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About the EMCDDA
The European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) 
is one of the European Union’s decentralised agencies. Established in 1993 
and based in Lisbon, it is the central source of comprehensive information 
on drugs and drug addiction in Europe.
The EMCDDA collects, analyses and disseminates factual, objective, reliable 
and comparable information on drugs and drug addiction. In doing so, it 
provides its audiences with an evidence-based picture of the drug 
phenomenon at European level.
The Centre’s publications are a prime source of information for a wide 
range of audiences including policymakers and their advisors; professionals 
and researchers working in the drugs field; and, more broadly, the media 
and general public.
The General report of activities is an annual publication providing a 
detailed progress report of the EMCDDA’s activities over a 12-month 
period. Published every spring, it catalogues the Centre’s achievements in 
each area of its annual work programme. The report is a useful information 
source for all those seeking comprehensive information on the Centre and 
its work.
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7Foreword
The European Monitoring Centre for Drugs and Drug Addiction hereby presents its fifteenth 
General report of activities to the European Parliament, the Council of the European Union, 
the European Commission, the Court of Auditors and the Member States, following its 
adoption by the Management Board. 
The report provides an account of the EMCDDA’s activities and accomplishments in 2009, 
the last year within the EMCDDA three-year work programme 2007–09.  
2009 was marked by the EMCDDA’s move into new installations at Cais do Sodré in August 
2009, providing the EMCDDA with improved working conditions and enhancing its visibility 
in Lisbon. 
Two European and international drug policy developments in 2009 had important 
implications for the EMCDDA’s activities. In January, the fifth EU action plan (2009–12) 
kicked off with five priority areas for action: improving coordination, cooperation and 
raising public awareness; reducing the demand for drugs; reducing the supply of drugs; 
improving international cooperation; and, improving understanding of the problem. The plan 
is more pragmatic, focused and targeted than its predecessors. The EMCDDA has reviewed 
its activities in light of the actions set out and developed or adjusted areas to better meet 
the plan’s needs.
In March, a new UN political declaration and plan of action was adopted at the United 
Nations’ Commission on Narcotic Drugs. In the debate leading up to the declaration, the 
EU and its Member States provided a strong voice for drug policies that are balanced, 
scientifically grounded and humane. These elements are reflected in the final declaration 
and there are signs that a more pragmatic and reasoned approach to what constitutes 
effective action is gaining ground.
Relations with the European Parliament were strengthened, particularly with the Committee 
on Civil Liberties, Justice and Home Affairs. In November 2009, the Centre presented the 
newly elected Committee the key findings of its Annual report on the state of the drugs 
problem in Europe.
On a more personal note, I would like to express my gratitude to colleagues on the 
Management Board and members of the Scientific Committee for their support and 
commitment to the objectives of the Centre and for their trust in selecting me to be their next 
Chairman. In this context, I wish to pay a special tribute to my predecessor Marcel Reimen, 
who ended his second mandate as Chair of the Management Board at the end of 
December 2009. A founding member of the Management Board since 1994, Mr Reimen 
served as Vice-Chairman (1998–2003), before being elected Chairman for a three-year 
mandate in July 2003. He was re-elected for a second term in December 2006. During his 
first mandate (2003–06), Mr Reimen steered the agency through enlargement to include 10 
new EU Member States in May 2004. His second mandate (2006–09) coincided with 
another EU enlargement (2007) and the recast of the EMCDDA regulation, which entered 
into force in January that year. This granted the agency a more active role in monitoring 
new drug use patterns and emerging trends. Mr Reimen made an outstanding contribution 
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to the development of the agency since it took its very first steps over fifteen years ago. In 
recognition for his commitment and leadership, he has been made Honorary President of 
the Management Board.
My special thanks also go to Wolfgang Götz, Director, the staff of the Centre and the Reitox 
national focal points for their dedication and professional commitment to the results 
achieved over the last year. 
At its July meeting, the EMCDDA Management Board decided unanimously to renew the 
mandate of Wolfgang Götz as Director of the EU drugs agency for a further term of five 
years starting 1 May 2010. I am looking forward to our collaboration in the years to come. 
João Goulão 
Chairman of the EMCDDA Management Board
9Introduction
2009 has been a year of change and new challenges. It has been a time to take stock of 
accomplishments so far, but also look forward to the future work of the agency. One of the 
key moments in 2009 was the conference organised to mark the agency’s fifteenth 
anniversary. This event covered a diverse and complex set of themes and highlighted the 
considerable variety of resources that exist in the EU. During discussions, it became evident 
that monitoring is an ongoing endeavour with its specific strengths and weaknesses, which 
produces useful and relevant outputs. Important synergies were clear between the 
conference debate and the EU drugs action plan, which speaks for how much the policy 
agenda has taken the key issues on board. Challenges for the future include the difficulty to 
sustain the existing system during a time of financial difficulties and how to constantly 
improve the sensitivity to change whilst remaining non-alarmist and reliable. This conference 
proved an exciting occasion which brought together many key players of not only the 
European, but also the international drugs field (1).
To continue on the theme of partnership, 2009 also saw a progression of cooperation with 
Europol. This involved starting work on a series of joint publications that bring together 
EMCDDA information and statistics on prevalence, health and drug research, with Europol 
data and knowledge on production, trafficking, markets and drug-related crime, offering an 
integrated analysis of the topics chosen. The first issue, on methamphetamine, was 
presented to the Horizontal drugs group in July. Another product, illustrating a different 
aspect of our partnership work, is the 23-language summary we published of the 2007 
European School Survey Project on Alcohol and Other Drugs (ESPAD) findings — to ensure 
the widest possible dissemination of the results in Europe. We hope to maintain and develop 
such forms of collaboration in the years to come.
International relations, and more particularly with candidate and potential candidate 
countries, also received special attention in 2009. One example of this was the conference 
hosted by the EMCDDA on behalf of DG RELEX (external relations) in Sintra, in November. 
The event brought together key European Commission staff, European agencies and 
representatives from accession and pre-accession countries, giving them all a forum to share 
information and experiences on the various trials and tribulations that exist on the road to 
accession. Follow-up from this conference is expected to continue in 2010.
On a practical note, this year’s report of activities uses a different structure from previous 
editions. The change involves a ‘reporting by objective’ approach that reflects the structure 
of the 2009 work programme. This will ensure greater coherence of the report itself whilst 
also allowing for a cross-check of results against expected outcomes. It thus represents a 
strong management tool for the Centre and European institutions alike.
I would add that the major operational change experienced by the EMCDDA in 2009 was 
undoubtedly the agency’s move from two buildings to one new building in Cais do Sodré, 
alongside our sister agency, the European Maritime Safety Agency (EMSA). I am sure that 
(1)  For more details on the conference, see proceedings online at http://www.emcdda.europa.eu/15years
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this unified structure and beautiful riverside setting will set the agency in good stead for 
meeting future goals and new challenges alike.
In 2009, the EMCDDA produced a vast range of high-quality publications, articles, 
presentations and other outputs, whilst also providing expertise to partner organisations in 
the drugs field. I would like to close by thanking the Management Board, Scientific 
Committee and Reitox network for their constant support and contributions throughout the 
year. I would also like to thank the agency’s staff who continue to enhance the agency’s 
reputation as ‘the reference point on drugs in Europe’ every day through their 
professionalism and dedication.
Wolfgang Götz 
Director
11
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Chapter 1 
Overview
This report covers the final year in the EMCDDA’s three-year strategy defined for 2007–09. 
The strategy covering this period clearly states that its main objective is to strengthen the 
agency’s core business of monitoring the drugs phenomenon and to ensure that maximum 
value is secured from investments made in this area. This means building upon the success 
already achieved in the information tools and mechanisms developed, to ensure that 
maximum analytical value is derived from the data collected, and that this information is 
then effectively disseminated in products tailored to the needs of the EMCDDA’s key 
audiences. To stress this approach, the strategy refers to the need to ‘speak’ to the Centre’s 
key audiences. As this strategic period comes to a close, the Centre must now look forward 
to the challenges it will face in the coming years. Taking on board the key issues raised and 
debated at its fifteen-year anniversary conference in May of 2009, as well as current trends 
and European concerns in relation to the drugs field, the focus for the new 2010–12 
strategy will move from not only ‘speaking’ to target audiences, but will take this to another 
level, through the compilation of even more comprehensive data and incisive qualitative 
analysis.
The EMCDDA’s achievements are only possible through partnership with national data 
providers and experts as well as with relevant EU bodies and international organisations. It 
is essential to mention here the importance of the Reitox network of national focal points 
and national data providers who act as the main interface between national data collection 
and expertise and the EMCDDA. And we acknowledge that Reitox support and input has 
been essential for accomplishing a large proportion of the work described in this report.
The core business of the EMCDDA is to monitor and report on the drugs situation in Europe. 
The objectives defined in 2009 build on fundamental aspects of the Centre’s work, 
identifying future priorities, adapting monitoring to meet future challenges and ensuring a 
more joined-up working approach. Identifying new trends and providing more effective 
communication complete the objectives.
The 2009 monitoring and reporting activities were divided into several main components:
•  refining data collection tools (treatment demand indicator, drug-related deaths, revision of 
the structured questionnaire on social reintegration and alternatives to prison)
•  developing an integrated approach to monitor specific areas related to drugs in Europe, 
for example: treatment, drug supply and supply reduction
•  stimulating analysis (namely on mortality cohort, general population surveys, polydrug 
use and drug-related infectious diseases).
The EMCDDA was very active in 2009 within the framework of the Council decision on new 
psychoactive substances, particularly in following up the ‘Spice’ phenomenon and related 
substances. The Centre also continued to concentrate efforts on developing an analytical 
focus on responses (for example, the Selected issue on sentencing statistics, an economic 
analysis of drug issues) and on developing its Best practice portal. The Annual report 
products continued to be improved and data validation strengthened, backed by the smooth 
day-to-day management of the data management tool known as Fonte.
In 2009, the EMCDDA undertook the most ambitious and demanding publishing programme 
to date. 17 individual titles representing 77 volumes were published and a substantial 
amount of new content developed for the website. Attention was paid to tailoring products 
to meet the needs of target audiences better and specific effort was made to tie the launch 
of products in with relevant events. The launch of the 2009 Annual report on the state of the 
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drugs problem on 5 November in Brussels was accompanied by national launches in nine 
Member States and attracted unprecedented press coverage.
2009 was an intensive year for developing new partnerships with decision makers, 
researchers, specialists at country, regional, EU and global levels. As the EMCDDA’s role as 
the reference point on drugs in Europe is affirmed, requests to communicate our results and 
messages face-to-face — in the form of visits from policymakers, presentations at 
conferences and talking to the media — are on the increase. Publishing in scientific journals 
is a growing channel for disseminating results too. Partnership activities provide an 
important outlet for our findings and help to heighten the impact of what we do and 2009 
has seen an increase in such work. The 15-year conference was vital for confirming and 
strengthening this kind of collaboration. It enabled a rich exchange of ideas and also 
identified routes for investigation and challenges for the Centre’s future activities.
The EMCDDA is composed of both statutory bodies and operational units that all work 
together in order to meet work programme and strategic objectives. The roles and 
responsibilities of the statutory bodies are presented in Chapter 3 of part I of this report. 
Within the agency itself, there are several operational units. These are: the Directorate 
(Director and his management team), two scientific units with three associated units, and 
two transversal support units.
The two scientific units are as follows:
Epidemiology, crime and markets (EPI) unit
The Epidemiology, crime and markets (EPI) unit is responsible for describing the overall drug 
situation based on social survey, public health and criminal justice data sets. One of its key 
tasks is to process, clean and analyse quantitative data and to manage qualitative and 
methodological information in order to describe and give an overview of drug use and its 
consequences; improve the comparability of data between countries; and analyse and 
understand drug data.
Activities conducted by the Centre in support of the Council Decision of 10 May 2005 on 
the information exchange, risk assessment and control of new psychoactive substances 
(Council Decision 2005/387/JHA) also fall under the responsibility of the unit.
Interventions, law and policies (RES) unit
The main role of the Interventions, laws and policies unit is to monitor responses to the drug 
problem in the EU. Its main objectives are to collect and analyse information on the 
measures taken in the EU Member States to curb the problem of drugs and drug addiction 
at individual or group level and examine interventions intended to reduce the harmful 
consequences of drug use. The unit also monitors national and Community strategies and 
their impact on the drug situation.
The three units that work in close collaboration with the scientific units are:
Reitox and international cooperation (RTX) unit
The main role of the Reitox and international cooperation unit is to coordinate a network of 
national focal points (NFPs), set up in the 27 EU Member States, Norway, the European 
Commission and in the candidate countries, hence forming the European information 
network on drugs and drug addiction.
Chapter	I
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Scientific partners and documentation (SCD) unit
The Scientific partners and documentation unit provides support to the core scientific units. It 
provides the secretariat for the EMCDDA Scientific Commiltee.
Communication unit
The work of the Communication unit includes: media relations, marketing, inter-institutional 
communication, special events, publications and distribution.
The two transversal support units (Information and communication technology unit and 
Administration unit) underpin the work of all the above.
This report gives details on the work implemented in 2009 in relation to the work 
programme for the period, as adopted on 4 December 2008 by the EMCDDA 
Management Board. For ease of reference, the main report has been structured by objective 
as defined in the work programme and as presented in Annex 1 to this report (2).
(2) See http://www.emcdda.europa.eu/html.cfm/index69563EN.html for the full work programme.
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Chapter 2 
Core business — monitoring and reporting on the 
drugs problem
Introduction
The core business of the EMCDDA is to monitor and report on the drugs situation in Europe. 
The objectives defined in relation to this activity in the 2009 work programme refer to 
building on fundamental aspects of the Centre’s work, identifying future priorities, adapting 
monitoring to meet future challenges and ensure a more joined-up working method, both 
within and outside the EMCDDA. Identifying new trends and providing more effective 
communication complete the objectives.
The 2009 monitoring and reporting activities were divided into several main components:
•  a refinement of data collection tools (treatment demand indicator, drug-related deaths, 
revision of the structured questionnaire on social reintegration and alternatives to prison)
•  development of an integrated approach to monitor specific areas related to drugs in 
Europe, for example: treatment, drug supply and supply reduction
•  stimulation of analysis (namely on mortality cohort, general population surveys, polydrug 
use and drug-related infectious diseases).
Similarly, in the framework of the Council decision on new psychoactive substances, the 
EMCDDA was very active in 2009, particularly in following-up the ‘Spice’ phenomenon and 
related substances, producing outputs on this topic. At the same time, the Centre continued 
to concentrate efforts in developing an analytical focus on responses (for example, the 
Selected issue on sentencing statistics, an economic analysis of drug issues) and to 
developing its Best practice portal. Lastly, the Annual report products continued to be 
improved, and data validation strengthened, backed by the smooth day-to-day management 
of the data management tool known as Fonte.
In addition, the EMCDDA has a role to communicate on its monitoring activities and provide 
support to debate and research in national and international circles. A full list of EMCDDA 
participation in key events in the drugs field organised in 2009 can be found in Annex 4 to 
this report.
Consolidate monitoring and reporting activities
Key epidemiological indicators — Specific objectives
The first objective set in the 2009 work programme is to improve and strengthen the 
implementation and coverage of the key indicators, in accordance with the work carried out 
in 2008, namely by clarifying and updating standards and criteria. In this respect, following 
an initial revision of the national reporting system in 2008, quality criteria were defined for 
national reports. An assessment of the implementation of the five key epidemiological 
indicators was also carried-out, the results of which were presented to the Management 
Board in December 2009. Similarly, activities of the national focal points (NFPs) were 
monitored and the data submitted by NFPs was cleaned, checked and amended. The Key 
Indicator Gateway (3) was also launched in 2009, and updated regularly.
(3) See http://www.emcdda.europa.eu/themes/key-indicators
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The second specific objective set in the work programme refers to reviewing and if 
necessary updating the definition and data collection requirements of the five  
key epidemiological indicators to ensure relevance and appropriateness. A first phase in this 
process involving a ‘critical assessment’ of the Treatment demand indicator (TDI) was 
implemented and then presented at the TDI expert meeting (14–15 September 2009). The 
full review of the indicator will be based on the results of this critical assessment, along with 
consultation with experts held in June and discussions held during the TDI expert meeting in 
September. Likewise, revision of the data collection tool on mortality cohort studies among 
drug users (Drug-related death indicator, or DRD) took place over the same period. Using a 
range of tools and feedback including expert comments, a first outline of the revised 
protocol was drafted. This will be completed in 2010. A one-day workshop on the mortality 
cohort was also organised in order to promote and stimulate mortality cohort data and 
analysis in the Member States. The ‘Prevalence among general population’ indicator (GPS) 
was the subject of a project launched with three countries. The aim of this project is to 
devise a common database structure for a set of core variables at national level. These will 
then be used for future collaboration between national experts and the EMCDDA for joint 
analysis work. The topic of polydrug use was chosen for the first trial of such collaboration. 
The on-going cooperation with ESPAD led to a scientific analysis of polydrug use based on 
the ESPAD database with an additional ad hoc data collection in some countries (field trial). 
Results of this were directly integrated into the Selected issue on polydrug use released on 5 
November (4). Similarly, the EMCDDA also started developing working tools to refine drug 
use estimates, namely comparison methods of national health surveys versus drug surveys.
In order to improve the estimation techniques of problem drug use and other intensive and 
risky patterns of drug use, a specific session on ‘PDU incidence estimation’ and workshops 
during the Annual expert meeting with contributions from EU experts was organised in 
October. Work on this will continue to be developed in the coming years.
Similarly, in 2009 an expert group was set up to consider revisions to the Drug-related 
infectious disease indicator (DRID) guidelines. Work in 2010 will take forward the 
recommendations made in 2009, focusing initially on the behavioural variables and then 
revising the methodological section of the guidelines.
Key meetings
13–14 January Lisbon Treatment demand indicator revision meeting
23–24 June Lisbon Expert meeting on the Key Indicator Prevalence and patterns of 
drug use among the general population (Population surveys)
8–10 July Lisbon Internal expert meeting and workshop on ‘PDU incidence estimation’
14–15 September Lisbon Annual Expert meeting on Treatment demand indicator (TDI)
12–13 October Lisbon Expert meetings on Drug-related infectious diseases (DRID)
15–16 October Lisbon Expert meetings on Problem drug use (PDU)
22–23 October Sofia National Annual Expert meeting on TDI ’Development of TDI-
perspectives and patterns of the National Monitoring Information 
system of Treatment Demand’
12–13 November Lisbon Expert meetings on Drug-related deaths and mortality among drug 
users (DRD)
Monitoring and reporting in support of the Council decision on new psychoactive 
substances (2005/387/JHA)
The specific objective under this heading focused mainly on the early warning system (EWS) 
and risk assessment guidelines. Key tasks implemented in 2009 therefore involved: regular 
(4) http://www.emcdda.europa.eu/publications/selected-issues/polydrug-use
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and timely notifications of new psychoactive substances and early warning; providing new 
substance profiles in the European Database on New Drugs (EDND); regular updates of 
substance profiles in the EDND and EWS reports and summaries by substance.
As a result of the above, 24 new psychoactive substances were notified for the first time in 
2009 and 34 new substance profiles opened. Also, an expert meeting on the Spice 
phenomenon and the annual EWS meeting were organised. Four different publications were 
produced on the Spice phenomenon: Understanding the ‘Spice’ phenomenon report, 
resulting from the Spice expert meeting (a regularly updated document based on new 
information), the EMCDDA Thematic paper on ‘Spice’, a drug profile on Synthetic 
cannabinoids and ‘Spice’ published on-line, and an editorial in the scientific journal 
Addiction (to be published in May 2010). A paper was also produced on khat and 
submitted to the Journal of Ethnopharmacology.
Three new drug profiles were published on the EMCDDA website in English, French and 
German and the whole set of 14 drug profiles was updated with the latest available figures 
available from the EMCDDA’s Statistical bulletin and the EWS. Similarly, Risk assessment 
operating guidelines were also drafted ready for publication. During the year, there was a 
regular exchange of information with the European Network of Forensic Science Institutes 
(ENFSI), and information exchange beyond the immediate scope of the Council decision 
(public health warnings to Reitox national partners) also occurred. Work carried out in 
2009 also involved producing summary tables of substances with a view to triggering the 
production of Joint reports, when needed. Such a report (on mephedrone) will be produced 
in 2010. In the framework of monitoring emerging trends, a conceptual framework to 
monitor online sales of psychoactive substances (Internet snapshots) was developed, along 
with a steering group.
Key meetings
6 March Lisbon Expert meeting ‘Spice and related synthetic cannabinoids’
4–5 June Lisbon 9th Annual meeting of the Reitox Early Warning System network
Annual reporting
In terms of ‘Annual reporting’, the work programme for 2009 identified the following 
specific objectives: to continue to improve the quality of the Annual report and accessibility 
of findings; to improve the Statistical bulletin and Country overviews and to develop the 
Centre’s quality assurance policy for data submitted and internal checks.
Overall, the quality of the Annual report has improved steadily since the adoption of its 
current format in 2004. The same applies to the Selected issues which since 2007 feature 
as separate printed publications, accompanied by a multilingual summary. In 2009, the 
report was released in 23 languages on 5 November. Certain improvements in terms of 
quality and accessibility of findings can be noted: summary tables for drug seizures and 
production estimates were introduced, which helped highlight key data in a more accessible 
format. The report also uses text boxes outside the running narrative in order to cover 
specific topics, and key statistics also have improved graphic presentation. An html version 
of the text was also integrated into the public website with direct links to underlying statistics 
and related products, thereby improving accessibility to relevant and complementary 
information.
Sound planning of the contents and the production process underpinned both the quality of 
the report and its timely publication. Member States and the Scientific Committee reviewed 
a draft version of the report to ensure quality control. A total of 26 Member States and eight 
members of the Scientific Committee provided comments on the 2009 draft.
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To complement the Annual report, a new graphical version presenting the key findings in the 
format of a Powerpoint presentation was produced and was very well received (43 slides 
with photos, graphics, maps and screenshots and accompanying script).
To improve the quality of the Statistical bulletin, table and figure listings were presented in a 
manner that makes them easier to read. A filtering system was also introduced for large 
results, to help refine searches in order to focus on key topic results.
Concerning the Country overviews, these were updated and streamlined with the Statistical 
bulletin, and published on the EMCDDA website in July.
In terms of developing the EMCDDA’s quality assurance policy, data validation was 
improved in a systematic manner, though work is still needed on validation processes. A 
common process to construct and test data collection templates has helped reduce greatly 
errors – these templates were provided in Excel and off-line format in March, which is 
earlier than in previous years. Also, revised guidelines for national reports were 
implemented in 2009 by all national focal points, ensuring that the new format for quality 
reports will be applied in 2010.
Monitoring of data delivery took place through Fonte, which was improved to be more user-
friendly in 2009. The list of all of the deliveries is now integrated into the checklist used for 
assessing the execution of grant agreements. In 2009, this checklist was improved in order 
to integrate recommendations made by the Internal Audit Service (IAS) report.
Annual reporting: events to launch the 2009 report
To mark the launch of the 2009 Annual report and associated products (Statistical bulletin, Selected 
issues, Country overviews, Drug profiles), the EMCDDA prepared a range of multimedia products to 
enhance communication and ensure a wide dissemination of results. These included a Message 
from the Director, three news releases, a Powerpoint presentation and a summary of the findings of 
the Selected issues (all in 23 languages), as well as MP3 recordings of the Director’s comments on 
the report (in English) and a promotional bookmark.
Events hosted included a briefing prior to the release of the report and public press conference 
(Brussels, 4 and 5 November), and a presentation to the European Parliament. Nine countries held 
national launches (Czech Republic, Denmark, Italy, Cyprus, Lithuania, Hungary, Netherlands, 
Portugal and Norway) in the same period. In total, 20 000 copies of the Annual report were 
distributed in 23 languages to support the launch. Within one week of the launch, 10 000 copies 
had also been downloaded from the EMCDDA’s website.
Revision of reporting tools
The 2009 work programme set three objectives in order to revise reporting tools. These 
include a continuation of the work started in 2007 to revise national data collection 
instruments, developing an integrated approach to monitoring drug treatment and harm 
reduction, along with the construction of a better framework for developing tools and data 
collection in the areas of crime and drug supply.
In 2009, the EMCDDA continued to revise national data collection instruments in 
collaboration with the national focal points. In particular, a revised version of structured 
questionnaires (on social reintegration and alternatives to prison) was agreed with the focal 
points. The revised versions will be introduced in Fonte in early 2010 for a new data 
collection the same year. The structured questionnaire on policy and institutional framework 
will also undergo revision in 2010.
With respect to developing an integrated approach to monitoring drug treatment and harm 
reduction, a new strategy to find appropriate data collection solutions was under development 
in 2009, and results were presented to the focal points throughout the year, to keep them 
updated. In 2009, there was also progress concerning the dissemination of information on 
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interventions for non-opiate drug problems. An update of the EMCDDA literature review on 
cocaine treatment was prepared and is available on the website (5). Similarly, updated 
country treatment overviews also placed online now include sections on the availability of 
interventions for non-opiate problem drug use (6). As regards harm reduction interventions, a 
monograph is being prepared on this subject, to be released in 2010.
In the areas of crime and supply, an in-house working group met and prepared a report on this 
issue. The document includes a first conceptual framework for describing and monitoring illicit 
drug supply and supply reduction in Europe. In the area of crime and markets, work continued 
with priority being given in 2009 to drug seizures (Standard table 13). On drug markets, a 
manual, including guidelines for collecting data on retail drug prices in Europe was finalised in 
2009, to be published in 2010. Two standard tables linked to population survey data were 
also prepared and will be piloted in 2010. In 2009, a review of 10 years of monitoring drug 
use in prison populations in Europe was started, to be the subject of a scientific paper in 2010.
Fonte/data management
The objectives defined in relation to data management for 2009 were: to assure a 
successful full complete year of Fonte reporting and validation by providing efficient 
maintenance, support and improved functions and data management procedures; to further 
develop and expand Fonte, rendering it more accessible and useful and also to consolidate 
EMCDDA knowledge and expertise through sharing of knowledge and streamlining.
The daily operations of Fonte were delivered and managed through various channels (help 
desk, data management team, Fonte project manager) and the system ran smoothly with the 
input of in-house and external IT services. Help videos and tutorials on the Fonte site also 
provided further assistance to users. In order to encourage prompt reporting and validation 
through Fonte, templates were provided earlier than in previous years (March) and the 
opening of Fonte brought forward one month, to June. An agreement was also reached to 
provide offline templates for use by the focal points in January in future years, and efforts 
made towards meeting this goal.
In terms of rendering the Fonte application more accessible, an improved working 
relationship with the national focal points led to an increased satisfaction expressed by Fonte 
users, and new functions and features were identified. A new version which enhanced speed 
and reliability was therefore implemented towards the end of 2009. External contractors will 
ensure that an even better version will be delivered in 2010. It is essential that consultation 
with NFPs occurs prior to developing data collection in Fonte. The NFP meeting in November 
2009 established the changes to be applied to the next round of data collection. As Fonte 
has now become central to the Centre’s data operations, its management structure has also 
been adapted, with a project manager being replaced by an operations desk responsible for 
the day-to-day support work, a Steering group that will review operational results and issues 
yearly, and a strategy and investment planning committee.
In order to enhance access to the data collected by the EMCDDA, a Data warehouse has 
been added to the Fonte structure.  This will allow the EMCDDA to query the data using 
SQL (Structured Query Language), a language common to many databases.  Work 
continues in house to gain the expertise to write the necessary extraction programmes.
Network management and capacity building
One key objective in this area for 2009 was to improve the capacity of national focal 
points in terms of implementing the five key epidemiological indicators and other core data, 
(5) http://www.emcdda.europa.eu/html.cfm/index40152EN.html
(6) http://www.emcdda.europa.eu/responses/treatment-overviews
General	report	of	activities	2009
22
and to develop training materials. As a general observation, we can say that despite 
considerable improvements in managing Reitox grants, an increasing number of focal points 
have faced serious financial and/or political difficulties for reasons beyond their control. The 
EMCDDA therefore took steps to assist these countries in their financial reporting directly 
on-site (Copenhagen and Rome in February and Ireland end-September). The Head of unit 
concerned also provided specific assistance to the Romanian NFP in situ.
A draft development strategy for the network was discussed with the Heads of focal points 
in November 2009. The aim here is to provide a common reference framework of Reitox’s 
work to external bodies, and also to identify actions and synergies for strategic decision-
making. The vision, mission statement and common goals for this exercise were adopted in 
November 2009 and the objectives and specific activities will be discussed in May 2010.
In terms of developing networking activities and partnerships in the field of research, the 
EMCDDA updated the information contained in the 2008 Selected issue on Drug-related 
research in European Member States (7), using the reporting countries’ national reports as a 
starting point. The methodology used in this process was discussed during an expert 
meeting held in October 2009 and then presented to the EMCDDA’s Scientific Committee.
Meetings of the Reitox network
27–29 May Prague 40th Reitox meeting of heads of focal points
18–20 November Lisbon 41st Reitox meeting of heads of focal points
Key meetings
5–6 February Lisbon Reitox Academy on cannabis market and production
13 March Lisbon Reitox Academy on prevention trials
17 November Lisbon Technical meeting on Reitox charter
18–20 November Lisbon Workshop on draft joint manual on building a national 
drugs observatory (NDO) with all NFPs
Developmental and conceptual activities
Under this heading, the 2009 work programme defined two main objectives: to continue to 
improve the focus, scope and appropriateness of data collection and reporting tools and 
mechanisms and to review the annual reporting infrastructure in terms of information needs 
in relation to the EU action plan.
A number of activities aimed at improving data collection mechanisms took place in 2009. 
These include a strategy on drug supply and supply reduction that was adopted in-house. 
This document includes a review of current data collection, and a strategy for future 
activities. A conceptual framework for monitoring illicit drug markets from an economic 
perspective was also integrated into the strategy. The feasibility for collecting wholesale 
drug prices was also assessed, and based on this a pilot study will be carried out with 
voluntary provision of such data by national experts in 2010.
In the area of data collection on responses in custodial settings, a Selected issue on 
sentencing statistics was published in 2009 (8). Following on from the Selected issue 
produced in 2008, public expenditure estimates were also improved, through further work 
(7) http://www.emcdda.europa.eu/html.cfm/index53913EN.html 
(8) http://www.emcdda.europa.eu/publications/selected-issues/sentencing-statistics
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on data collection instruments. A new Standard table on public expenditure was developed 
(results will feature in the Annual report 2010).
For obtaining more up-to-date estimates on Injecting drug users (IDU), an assessment was 
carried out with eight participating volunteer countries, and a report will be available on the 
subject in 2010.
In terms of information needs linked to the EU action plan, a number of questionnaires for 
monitoring responses were revised in 2009. More will be revised in 2010. A review of 
available information for the annual progress of the EU drugs action plan for 2009–12 was 
also transmitted to the Commission.
Key meetings
31 August–1 September Lisbon Preparatory meeting on SQ28 on social reintegration
7–8 September Lisbon Expert meeting on the revision of SQ28 on social reintegration
30 October Lisbon Drug-related research information expert meeting
Enhanced analysis of data
Key epidemiological indicators
The key indicators used by the Centre are essential to its work. In 2009, the objectives were 
to improve the analysis of data, carry out cross-indicator analysis and perform an analysis 
of specific issues of particular relevance to policy.
Work to improve the analysis of data involved performing new analyses in collaboration with 
RIVM Netherlands on the Drug-related infectious diseases (DRID) Key Indicator. Ten new 
analyses were carried out by different experts, and nearly half were finished by the end of the 
year. A progress report on this issue was produced in April and the expert meeting on the 
DRID resulted in further data provision for the analyses. The first batch of reports focuses on 
the links between HIV and hepatitis C (HCV). This work will continue to develop in 2010.
In order to gain greater value from data through cross-indicator analysis and to continue the 
work to develop methods to assess intensive and problematic forms of drug use in general 
population surveys, validation studies were carried out in 2009. The results of these studies 
were provided to the EMCDDA for Spain, France and Italy. Work in this area is also 
planned for three more countries. The preparatory work for two forthcoming publications 
(Selected issue on injecting and harm reduction monograph, due in 2010) also provided an 
opportunity for cross-indicator analyses of infectious diseases and injection patterns and 
their relation to harm reduction measures. A paper on the issue was prepared and 
published in the American Journal of Public Health (9).
In order to better identifying the specific components of drug-related mortality (e.g. AIDS, 
HCV, accidents, suicides) a paper was drafted on HIV-AIDS mortality attributed to drug use: 
contributions and comments on this were received from Member States and the ECDC. 
Similarly, a preparatory report on the problem of non-fatal opiate overdoses in Europe was 
also prepared, and options to take this further will be discussed with the authors in 2010. 
Some work on the relation between social exclusion and drug use was also carried out and 
an analysis of this was included in the social reintegration section of the 2009 Annual report.
(9)  Wiessing L., Likatavičius G., Klempová D., Hedrich D., Nardone, A. and Griffiths P., ‘Associations between 
availability and coverage of HIV-prevention measures and subsequent incidence of diagnosed HIV 
infection among injection drug users’, American Journal of Public Health, Volume 99, No 6, p. 1049, 
2009.
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Analysis of patterns and trends
The work programme for 2009 set the task of ensuring that the European level analyses of 
patterns and trends were up to date. Work carried out over the year involved a number of 
key activities, and trends analyses based on Key Indicators were integrated in the Annual 
report for 2009, the Statistical bulletin and the Country overviews.
Specific analyses of patterns and trends resulted in two Selected issues. The first on 
polydrug use covered several population groups: school children, young adults and problem 
users. It also considered the role of alcohol, health consequences of this pattern of use, and 
responses (10). A second on sentencing statistics provided information on drug law offences 
and outcomes, the problems of separating sentencing of users and traffickers, penalties and 
directing users to treatment (see footnote 6 for link). An analysis of European trends and 
associations of HCV and HIV in injecting drug users was also published in Addiction 
magazine in 2009 (see articles list in Annex 4).
The second ambition in the work programme was to improve the statistical approach for 
analysing medium and long-term trends by synthesising data from various sources. To this 
end, in order to analyse the validity of a new method to estimate heroin use in Europe, a 
pilot study was carried out, to be continued in 2010. The results of this exercise were 
already included to some extent in the 2009 Annual report.
In respect to the objective of improving understanding of polydrug use in mortality, work 
was carried out to provide more insight in relation to specific drug combinations. The results 
of this work feature in the Selected issue on polydrug use, namely some interesting new 
results on cocaine, heroine and methadone interactions.
In order to better link the analysis of demand and supply data, the 2009 Selected issue on 
polydrug use brought together such information in one publication. Preparatory work for 
2010 Selected issues was also undertaken with this in mind. With regards to estimates on 
drug consumption (based on a linkage between demand and supply data), the 
methodologies used in various studies worldwide were reviewed in 2009. The review will 
serve as the basis for a scientific paper in 2010. The EMCDDA also continued to work on 
indicators and approaches to measure and compare public expenditure in the drugs field. A 
technical paper on non-labelled public expenditure on prisons was also drafted to be later 
published in a scientific journal.
Analytical focus on responses and best practice
The aim in 2009 in terms of best practice focused on improving reporting from different 
fields of intervention. To this end, the Best practice portal on the EMCDDA website was 
maintained, and an extra module on selective prevention and treatment were also launched, 
in close collaboration with members of the Centre’s Scientific Committee. The second 
objective on responses and best practice related to improving analyses on the extent to 
which European responses meet estimated needs. In 2009, and following further analysis of 
data on opioids substitution treatment (OST), for the first time the EMCDDA produced an 
overview of the involvement of general practitioners in the provision of opioids substitution 
treatment in Europe, shown in a map contained in the Annual report. This data was also 
made available via the Statistical bulletin.
Along similar lines, work continued on national strategies, coordination mechanisms and 
evaluation methodology, and reported in the Annual report. The Selected issue on 
sentencing statistics also provided clearer data on responses. European discussion on 
(10) http://www.emcdda.europa.eu/publications/selected-issues/polydrug-use
Chapter	2
25
addiction medicine was encouraged via the recently launched Addiction Medicine website 
and Beta version of Info-base ADIMED (11).
The final objective under this heading for 2009 was to develop further the economic 
analysis of drug issues. To this end, the Centre explored alternative methods for registering 
the economic benefits of drug use treatment programmes. A project on the comparative 
cost-effectiveness of treatment intervention was launched, which will help elaborate a 
methodological theory for a comparative cost-effectiveness analysis of methadone and 
buprenorphine in the management of opioid dependence. A scientific paper was prepared 
and submitted for publication in a scientific journal on this topic.
Similarly, an overview of the economics of illicit drugs using a case study approach led to 
two peer reviewed papers that were published in an international drug policy journal (12) 
and another paper on modelling the heroin, cocaine and cannabis markets was accepted 
to be published in the Journal of Narcotic Drugs.
Key meetings
16–7 March Lisbon US-EU cross national study on prevention
21 September Lisbon Legal Correspondents meeting
12–13 November Lisbon Expert meeting ‘Methodology to estimate Non-labelled Prison Drug-
Related Expenditure in the EU’
Communicate more effectively with key audiences
High-quality, timely and accessible products
The EMCDDA’s work programme for 2009 was the most ambitious and demanding 
publishing work programme to date. Within this featured various aims and objectives, 
particularly geared towards tailoring products produced by the EMCDDA in order to meet 
the needs of target audiences better. As a result of such measures, 17 individual titles 
representing 77 volumes were published and a substantial amount of new content 
developed for the website. In 2009, specific effort was made to tie the launch of products in 
with relevant events. A comprehensive list of outputs can be found in Annex 4.
Timely production of publications included, for example, meeting the target date for the 
publication of the annual reporting products in two stages: the Statistical bulletin, Country 
overviews and National reports were released in July; and the Annual report in 23 
languages, two Selected issues (one on sentencing of drug law offenders and the other on 
polydrug use) and updated Drug profiles in November.
Similarly, the EMCDDA demonstrated that it could respond in a timely way to demand 
for information on topics of policy interest by publishing a Monograph on the 
neurobiology of addiction with an accompanying Policy briefing on neurobiological 
research. It also published in the Insights series a publication on Internet-based drug 
treatment interventions and was able to respond to the growing and rapid need for 
information on ‘Spice’ with a thematic paper examining the substance and its emergence 
on the market.
Outputs for the 15-year conference ‘Learning from the past, looking to the future: identifying 
Europe’s information needs for effective drug policy’ were fast-tracked in the spring. Apart 
(11) See http://www.emcdda.europa.eu/responses/addiction-medicine
(12) See table ‘EMCDDA technical reports, papers, reviews and articles’ in Annex 4 for details. 
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from the conference materials and website, 22 posters on aspects of the EMCDDA’s work 
were developed. Conference proceedings were published and also available online by the 
end of the year.
One initiative to support the EMCDDA’s ongoing partnership with ESPAD was the 
publication of a multilingual summary of this important study on school-aged children’s drug 
taking in 23 languages, hence guaranteeing a broad dissemination of results to the non 
English-speaking public in a timely manner.
The EMCDDA–Europol joint publication series was introduced to pool EMCDDA and 
Europol knowledge and produce prompt information on specific drugs and the first issue on 
methamphetamine was released in the summer.
Twelve news releases, six fact sheets and additional press materials (PowerPoint 
presentations, MP3s, Message from Director) were produced in 2009. These items marked 
the launch of a steady stream of EMCDDA products and services. The press room area of 
the website was revamped in the second half of the year to present a more multimedia 
approach. The EMCDDA began using Twitter to disseminate news in 2009. Four printed 
and online editions of the quarterly newsletter Drugnet Europe were also produced.
Work in 2009 also continued to develop tools to assist in preparing high-quality products 
including on-going development of the EMCDDA style guide and a multilingual glossary 
project, conceived with the senior terminologist of the Translation Centre for the Bodies of the 
European Union (to be implemented in 2010). Similarly, an in-house system of recording 
requests for both editing/language revision and web work (called E-Com) was launched. This 
enables all staff members to access a qualified pool of staff in the Communication unit, to 
revise and edit work and provide other associated services in a structured manner. This helps 
meet deadlines more effectively, and also ensures better planning and use of resources.
The publications database was expanded to include grey literature. A set of approximately 
50 keywords was defined and each publication tagged accordingly. At the end of the year, 
a new entry page was launched to implement these changes, thereby making the 
publication database even more user-friendly and products more findable.
In order to make the information on the website easier to access, thematic pages were 
developed for neuroscience, young people and research. Thematic web pages bring 
together in a single place all available EMCDDA resources on a particular topic.
In terms of releasing products — preferably in conjunction with a relevant event in the field 
concerned — various press and marketing actions were organised in 2009. EMCDDA 
product launches included the usual news materials, promotion via the newsletter Drugnet 
Europe, the public website, the EU Bookshop and specialised news services, such as Daily 
Dose and DS Daily. EMCDDA products were also displayed at key events (Commission on 
Narcotic Drugs, CLAT 5 conference, 52nd International ICAA conference on dependencies). 
This year, to mark the International day against drug abuse and illicit trafficking (26 June), 
the two products on neuroscience were launched via a news release. Likewise, a press 
briefing at the end of the May conference delivered its results to Lisbon-based journalists. A 
group of political and media events in Brussels publicised the 2009 Annual report.
In order to further improve the quality of products and efficiency of the editorial process, the 
Communication unit continued to work closely with the scientific units and scientific writers. 
The latter have helped ensure that the quality of material submitted to editing is of a higher 
quality than previously. Likewise, work continues upstream with suppliers to ensure they have 
the necessary background and contextual information to deliver efficient results in terms of 
translation and production. To this end, a seminar was given to the translators in the 
Translation Centre on the EMCDDA’s role and translation needs. A two-day session with 
colleagues from the Publications Office in Luxembourg also gave the opportunity to provide 
more key information on products and processes and enhance our collaboration.
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Dialogue with stakeholders and partners
This objective is in line with the EMCDDA top-level priority to ‘communicate more effectively’ 
with key audiences (policy, science, practice and citizens), and requires analysing target 
groups and soliciting feedback in line with the communication strategy.
The media are a major conduit to permanently raise awareness and reach the various 
EMCDDA target audiences. The media relations and marketing sector therefore invests time 
in nurturing partnerships with journalists via press office activities and press events. 
Noteworthy in 2009 was collaboration with various entities on documentaries or other 
visual productions: ARTE produced a major documentary on cannabis (aired in February 
2010) and the Italian NGO Coges produced a DVD on prevention.
The media sector continued its monthly reporting cycle on press requests and coverage via 
press reviews, following the format introduced in 2008 (summary/qualitative analysis of the 
type of request and coverage achieved; quantitative overview). Press reviews were also 
compiled in the wake of key events (EMCDDA 15 year conference; 26 June and the 2009 
Annual report launch).
Incoming press services were analysed for relevant articles which were made available to 
staff on the Internet press area.
Through a process of consultation, partners play an important part in assuring the quality of 
the Annual report, Selected issues and Statistical bulletin. Partners’ comments on the draft 
publications are taken into account and they are informed of the outcome. In 2009, the 
Scientific Committee spent part of their meeting in November reviewing the various chapters 
of the Annual report.
The number of information requests from the general public continues to grow and the 
EMCDDA received 60 % more in 2009 than in the years before. The majority of these 
requests showed increased interest in the agency’s publications. A restructuring of this 
service has made it possible to answer these requests quickly.
More specifically, in order to meet the objective of facilitating access to drug related 
science and research and to promote exchange with the scientific community, a thematic 
area was created on the agency’s website devoted to EU and national drug-related 
research. It offers up-to-date information on resources allocated to this field, including calls 
for proposals and tenders, information on fellowships and other research opportunities, as 
well as links to EU and national research sites. Country overviews provide a structured 
synopsis of the drug-related research in the country and are updated once a year. An 
internal strategy paper on scientific publishing was also drafted, and two seminars were 
held in collaboration with the Scientific Committee and the International Society of 
Addiction Journal Editors (ISAJE). To support this work, the documentation centre in the 
EMCDDA was expanded with the move to new premises. Staff in the agency has online 
access to around 20 electronic journals and databases and the documentation centre 
responded to 504 literature enquiries on a wide range of topics in 2009.
In order to better facilitate sharing of experience and examples of best practice, the best 
practice portal was expanded to include sections on selective prevention and 
pharmacological and psychological treatment, whilst work started on three related Manuals, 
to be released in 2010. Similarly, the EMCDDA continued its collaboration with the 
European Masters on Drugs and Alcohol Studies (EMDAS) involving several universities. In 
2009, pilot modules were developed and peer reviewed by the Scientific Committee.
With respect to civil society, attention was paid to ensuring that debates and actions from 
this sector were reported on. The EMCDDA provided support for the launch of the European 
Commission’s European Action on Drugs (EAD) which is designed to provide European civil 
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society with a platform to raise awareness and commitment on drugs and drug abuse and 
to promote dialogue and the exchange of best practice.
Cohesive representation and communication
Brand-related activities were once again central to communication work in 2009 with new 
staff being trained in the EMCDDA corporate identity. In terms of external communication, 
various items linked to the Annual report were prepared to help staff prepare for the launch 
of the report and ensure coherent messaging. To help raise the quality of presentation skills 
for staff in-house, two training courses were offered (Director and Heads of unit; and project 
managers) in radio, television and other media scenarios.
‘EMCDDA, your reference point on drugs in Europe’
As the EMCDDA’s role as the reference point on drugs in Europe is affirmed, requests to 
communicate our results and messages face-to-face — in the form of visits from 
policymakers, presentations at conferences and talking to the media — are on the increase. 
Publishing in scientific journals is a growing channel for disseminating results too. 
Partnership activities with our international, EU and national partners also provide an 
important outlet for our findings and help to heighten the impact of what we do. An 
increased number of citations have been noted in printed and online media. Evaluating the 
growth in this area is a task for the 2010 work programme.
As per previous years, in 2009 the EMCDDA held an exhibition stand at various events, 
such as the Commission on Narcotic Drugs (CND) in Vienna, the EC’s conference on drug-
related research in Brussels, the ICAA (International Council on Alcohol and Addictions) in 
Estoril and the Frankfurt Book Fair displaying publications and answering questions. An 
increased number of other events were supported, by sending customised publication 
packages, posters and roll-ups to conferences and meetings such as the Horizontal Drugs 
Group (HDG), the CLAT conference in Porto and the London online information exhibition. 
This service was included in the aforementioned E-Com tool at the end of 2009, which will 
further systemise and enhance it in 2010.
In the light of the EMCDDA’s move to new premises in August, branding and equipping the 
building’s common areas for promotional events was a priority in 2009. The move also 
meant that all of the Centre’s stationery items had to be revised and reprinted in 2009.
As already mentioned, intensive work was also carried out in 2009 in relation to the 
branding of two EMCDDA conferences in May and December (see box below). This 
entailed liaising with designers and printers in the conception of the conference brand and 
accompanying production of conference materials, both paper-based and promotional 
(bags, pens, etc.).
A new EMCDDA promotional brochure was produced in 25 languages during 2009 
outlining its main mission and activities and highlighting the EMCDDA slogan.13
The conference Identifying Europe’s information needs for effective drug policy organised in Lisbon 
in May marked the Centre’s fifteenth anniversary monitoring the drugs situation in Europe. Around 
350 participants from the EU and beyond attended the event, which was structured around the 
themes of policy, practice, trends and horizons. The programme for the event included over 40 
scientific presentations, and the high-level nature of the event, both in terms of participants and 
relevance, led to the Prime Minister and President of Portugal giving speeches at the opening and 
closing sessions, along with representatives from EU institutions and key EMCDDA partners. The 
conference was vital for confirming and strengthening collaboration and partnership, providing 
visibility for the agency in both national and international press. The event led to a rich exchange 
of ideas and identified routes for investigation and challenges for the Centre’s future activities (13).
(13) For Conference proceedings, please see http://www.emcdda.europa.eu/html.cfm/index95271EN.html
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Key meetings
2–3 February Lisbon ISAJE seminar on scientific publishing for staff and meeting with 
scientific writers
29 September Lisbon Seminar on scientific publishing (given by John Strang)
Strengthening cooperation and communication with partners
Cooperation with European institutions
Throughout 2009, staff from across the EMCDDA collaborated closely with DG JLS D3, 
providing various forms of support when needed. This is also true of DG SANCO, and to a 
lesser extent DG TREN, Eurostat, and other DGs. Coordination meetings with both DG JLS 
and DG SANCO occurred throughout the year, and the EMCDDA was also consulted and 
involved in meetings linked to the Czech and Swedish Presidencies of the Council. The 
EMCDDA’s expertise means it was also invited to attend various groups and think tanks 
organised by the Commission and the agency’s Director maintained relations with high-level 
representatives from the EU institutions on a regular basis. Key publications by the agency, 
such as the Annual report, were launched to the press in the European Parliament, in close 
collaboration with the Commission’s press service.
Cooperation with European agencies
Work with European agencies focused mainly on collaboration with Europol (14) and the 
ECDC. The EMCDDA’s Director met with both the outgoing and incoming Europol Directors 
in 2009, particularly in light of joint publications to be produced from 2009–12. 
Collaboration in 2009 involved the drafting and finalising of a questionnaire to collect and 
report on wholesale drug prices. In communication terms, a specific information brochure 
entitled ‘EMCDDA–Europol cooperation: Joint publications on illicit drugs’ was produced in 
2009 and work commenced on the series of joint publications between EMCDDA and 
Europol. An Early Warning System operates between Europol and the EMCDDA, which 
helps quickly identify new psychoactive substances. Within this framework, in 2009 a 
meeting was organised to discuss five new substances with the potential to trigger the 
launch of a joint EMCDDA–Europol report.
In terms of cooperation with ECDC, a cooperation agreement signed in 2007 involves 
regular data monitoring and exchange of information. These include among others, the 
monitoring of the seroprevalence of HIV, HCV and HBV among injecting drug users as well 
as behavioural surveillance among this risk group. During 2009, participation at events and 
meetings and publishing joint scientific articles enhanced the reciprocity between the 
organisations. A Memorandum of Understanding between the EMCDDA and the European 
Medicines Agency (EMA) was also prepared during the same period and will probably be 
signed in 2010. Both formal and ad hoc mechanisms already operate between the two 
agencies, which will undoubtedly be strengthened by this agreement. Also in 2009, the 
EMCDDA increased cooperation with the European Police College (CEPOL). The EMCDDA 
contributed to its seminars and workshops on illicit drugs by giving presentations and 
moderating discussions. The cooperation with CEPOL on drug supply and supply reduction 
in Europe will be continued in the next years.
(14)  For an example of EMCDDA–Europol collaboration, see: http://www.emcdda.europa.eu/html.cfm/
index82068EN.html
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In relation to other EU agencies, the EMCDDA attended the annual meeting of the Heads 
of Communication and Information Network (HCIN) in Parma where all agencies come 
together to discuss communication strategy, web management and other public relations 
activities. The agency was also present at the meeting of HCIN delegates with the EC 
Commissioner for Communication, Margot Wallström on 16 March in Brussels. This 
encounter focused on how to communicate Europe beyond Brussels. In 2010, the 
EMCDDA will head the HCIN network and during 2009 there were some preparatory 
meetings for this.
Collaboration with other international partners and with regional and 
international organisations
On cross-cutting issues, work to strengthen relations with international organisations and 
other EU agencies led to a joint publication of the summary of the 2007 ESPAD results in 23 
EU languages (15). Work with Health Behaviour in School-aged Children (HBSC) continues 
with fieldwork being undertaken in preparation for the forthcoming HBSC survey for 
2009/10.
Work with the United Nations Office on Drugs and Crime (UNODC) was also strengthened 
in 2009, through a two-day visit to the agency by UNODC staff and EMCDDA 
participation at several meetings organised by the former. The EMCDDA was also invited to 
join the steering group for the UNODC project entitled ‘Promoting Best Practices and 
Networking for Reducing Demand for and Harm from Drugs’. The Director and a delegation 
of key staff from the EMCDDA also made a significant contribution to the high level segment 
of the 52nd Commission on Narcotic Drugs held in Vienna in March. In addition, in 2009 
the EMCDDA played an important role in the revision process of the UNODC data-
collection tools by supporting EU Member States in contributing to the process and 
participating in associated expert groups.
Under the terms of the existing Memorandum of Understanding, the EMCDDA and the 
World Customs Organization (WCO) exchanged expertise in the development of 
methodological standards and shared information on drug seizures. In 2009, participation 
at events and meetings strengthened the relations between both organizations and resulted 
in a draft document on their future cooperation which will probably be finalised and signed 
in 2010.
Work also continued with partners involved in the issues of drugs and driving (meeting 
hosted by the EMCDDA in May on road surveys and hospital studies), the World Health 
Organization (WHO) — the EMCDDA co-hosted the health in prisons conference, Madrid; 
cooperation with the WHO-HIP network on health in prisons and the Latin Conference on 
Harm Reduction. Collaboration with the Pompidou Group of the Council of Europe also 
continued, with the EMCDDA participating as an observer in meetings of the Group’s 
Permanent Correspondents. The chairman of the Pompidou Group convened the EMCDDA, 
WHO, UNODC, the European Commission and the European Presidency Troika to an 
interagency meeting in January 2009. The EMCDDA also took part in the various Pompidou 
Group thematic platforms. Collaboration with the Inter-American Drug Abuse Control 
Commission (CICAD) was further developed along two themes: mutual support for 
implementation of the Memorandum of Understanding between the two organisations, 
including participation in a workshop in Brussels in June 2009, organised by AIDCO, and 
cooperation and consultation on the Joint manual on building national observatories, to be 
released in 2010.
(15) http://www.emcdda.europa.eu/publications/espad
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External visitors to the EMCDDA
During 2009, EMCDDA staff successfully coordinated and organised 29 external visits. 22 of these 
were to improve visitors’ understanding of the mandate and activities of the EMCDDA, and the 
remainder focused on discussions about possible cooperation and exchange of technical 
knowledge in specific scientific areas (for example, the cocaine situation, cannabis aspects, the 
drug situation in Portugal, etc.).
Delegations included 10 visits of diplomats (Colombia, Croatia, Iran, Malta, Mexico, Moldova, 
Sweden, Switzerland, Ukraine and USA), 5 national country representations (Brazil, Croatia, 
France, Israel and the UK) and three Central Asian countries), 12 meetings with possible partners in 
the drugs field (from Australia, Austria, Germany, Greece, Open Society Institute, Portugal, Red 
Cross Society Canada), and one technical meeting on cooperation activities with Europol.
Key meetings
9–10 February Lisbon EMCDDA–JLS coordination meeting 
12–13 May Lisbon DRUID (driving under the influence of drugs, alcohol and 
medicines) WP2 meeting on road surveys and hospital studies 
11–12 June Lisbon UNODC–EMCDDA coordination meeting
Scientific community and professional networks
In 2009, the EMCDDA set the objective of promoting scientific partnerships and professional 
networking. To this end, the agency provided support to DG JLS in the preparation of the 
conference held in Brussels on 24–25 September, entitled ‘Bridging the research gap in the 
field of illicit drugs in the EU’. The agency’s Director made a speech at the opening session 
and members of our Management Board, Scientific Committee and staff, as well as 
members of national focal points, attended the event.
The Horizontal Working Party on Drugs elaborated Council conclusions on strengthening EU 
research capacity on illict drugs (16) which were adopted in December. The EMCDDA, with 
its Scientific Committee and Reitox network, was invited to provide input and to disseminate 
information on drug-related research from Member States and the EU. Similarly, for DG 
Research the agency disseminated information on various calls for proposals linked to 
activities within the 7th Framework programme for research via its website and other 
communication channels.
In 2009, the EMCDDA also became a corporate member of ISAJE (International Society of 
Addiction Journal Editors), participated in its yearly meeting and organised a seminar on 
publishing for scientific staff with the support of the former. The EMCDDA also continued to 
maintain regular links with Eurolib: a network of European institutional libraries as well as 
other Europe-wide organisations in this area.
Technical assistance to candidate and potential candidate countries
In 2009, work continued to prepare candidate and potential candidate countries for their 
participation in the work of the EMCDDA. A CARDS project (Community Assistance for 
Reconstruction, Development and Stabilisation) involving Albania, Bosnia and Herzegovina, 
the former Yugoslav Republic of Macedonia, Montenegro and Serbia ended in October 
2009, and activities within the IPA I project with Croatia and Turkey ended in November. 
The EMCDDA also took the initiative to organise on behalf of the Commission a high-level 
conference with European agencies and IPA beneficiaries in November in Sintra, financed 
via IPA II. This conference brought together around 120 participants from eight beneficiary 
(16) See CORDROGUE 78, 7.12.2009, point 4.4.
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countries and also 15 European agencies, as well as representatives from the European 
Parliament, European Commission, Portuguese authorities and other international 
organisations. The conference provided a unique platform for exchange and discussion 
between the various parties represented on the approaches, tasks and challenges posed by 
accession. The contract for an IPA III project involving Albania, Bosnia-Herzegovina, 
Croatia, the Former Yugoslav Republic of Macedonia, Montenegro, Kosovo (under UNSCR 
1244/99), Serbia and Turkey was signed at the end of November for a total duration of 23 
months (until November 2011). The main objective of this IPA project is to prepare the IPA 
beneficiaries for participating in the EMCDDA’s activities, more particularly focusing on 
strengthening their capacity to establish, at their national level, a drug information system 
compatible with the one used by the agency.
International cooperation with non-EU countries
In relation to the agency’s work with non-EU countries, in July 2009, the Management 
Board adopted a document entitled ‘Implementation of the strategy on international 
cooperation with third countries’. Work on the final text of a Memorandum of Understanding 
with Ukraine also continued over this period. The EMCDDA was also asked to take part and 
make a presentation on its experience in technical cooperation and national focal point 
building activities at the first workshop organised in Brussels for EU Delegations from Latin 
America by AIDCO.
Similarly, the EMCDDA Director continued to develop partnerships with non-EU countries, 
including receiving a delegation from Croatia, headed by the Deputy Prime Minister.
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Chapter 3 
Support activities — improving efficiency and 
effectiveness
Administrative support
Planning, reporting and legal matters
In 2009, efficiency, effectiveness and transparency in planning, reporting and monitoring 
were improved. The processes for the preparation of multi-annual and annual work 
programmes and monitoring the implementation and reporting on achievements of 
EMCDDA activities in 2009 were improved and the annual work programme for 2010 and 
the three-year work programme covering 2010–12 were also prepared with a better 
structure and results-oriented approach. This strengthened links between planned objectives 
and outputs and in the future should encourage the development of new tools for monitoring 
and reporting on the EMCDDA’s performance.
In this context, the Centre undertook a preliminary analysis of possible performance 
indicators to use in relation to the implementation of its work programme. Similarly, the 
budget earmarked for the implementation of the work programme was improved in 
accordance with the principles of activity based management. A first assessment of the 
possible solutions provided by the ABAC/SAP system to develop activity based budgeting, 
management and accounting was also carried out.
Human resources management
The objective set for human resources management in 2009 was to implement and monitor 
rules, procedures and tools for managing and developing EMCDDA staff. Throughout the 
year, the agency remained close to full employment with 78 officials and temporary agents 
out of a total of 82 authorised posts in the Establishment Plan and 22 contractual agents.
The human resources team put significant effort into the development of two HR policies: 
staff performance appraisal and promotion. The two processes were developed in a manner 
that provided support to both staff and management. Furthermore, a full assessment of the 
appraisal exercise was carried out and corrective measures were proposed which will be 
implemented in the 2010 exercise. Likewise, the identification and prioritisation of training 
needs, with special attention to the results of the staff appraisal exercise, were strengthened. 
Special attention was given to training for middle and top management. Coaching on 
administrative and managerial issues was further developed on the basis of the experience 
gained in 2008.
The EMCDDA continued to inform the European Data Protection Supervisor of its HR processes, 
in accordance with the provisions of the Regulation on the protection of personal data.
Following requests from other EU agencies, the EMCDDA’s human resources management 
services provided expertise and support on several HR issues (namely by taking part in 
selection panels, providing them with training on HR processes such as appraisal of staff 
and promotion, etc.).
Once again, the EMCDDA was the first agency to send its three-year staff policy plan (SPP) 
to the Commission’s services. This exercise was again successful in terms of both its contents 
and its timely delivery.
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The EMCDDA further developed its in-house capacity, tools and processes for human 
resources management. New implementing rules and policies were drafted in order to 
complete a coherent and comprehensive legal framework for this. At the same time, HR also 
worked hard to develop a strategic approach for HR management. For this purpose, an 
internal working paper was produced, including a diagnosis and proposals for further 
development in this area.
Financial management and accountancy
In terms of implementing appropriate processes and procedures for financial management 
and control, the end-of-the-year operations management was improved (closure, carry-over, 
entering of 2010 budget) and new reporting tools were set up to improve budget execution 
monitoring. Similarly, intranet-based financial support services were developed and 
improved.
Regarding missions, an ex post verification of transactions for expenditure concerning 
missions was launched in the 2nd semester 2009 and the rules and processes for missions 
and meetings were updated to align them with the Commission’s revised rules.
The financial services sector was involved in launching 373 tendering and contracting 
processes (17). The daily management of contracts and budgetary transactions, including 
ex-ante verification and bank transfers, represented a total of 1 627 operations (18).
In accounting terms, the ABAC/SAP system for budget management and accounting was 
fully implemented in 2009. In this context, a new set of reports was developed in order to 
ensure efficient monthly reconciliation and better monitoring and control of EMCDDA bank 
transfers. An improved payment process was also implemented, relying on the Swift 
network.
ICT developments for improving organisational efficiency
Undoubtedly the main challenge for this sector in 2009 was the move from two locations to 
one new building. The move involved making the necessary preparations for a phased 
removal for all IT services, including network, communication and servers, from two 
buildings to a third. The ICT department coordinated all the adjustment works needed to 
implement the operational and security requirements for the new premises. It also 
participated and supervised the transport and subsequent integration of all the services, 
ensuring all the required configuration, data adjustments and tests. The ICT infrastructure 
was developed in the context of the move in a manner that reflects the organisation’s 
development; thus, the next phase of the storage area network project was fully aligned 
with the agency’s new requirements.
The project was particularly enhanced in implementation terms by a very close 
cooperation between Administration and ICT. A new staff data management application, 
developed in-house, streamlined the work in Human resource management. In addition, 
work with the new central financial management system, ABAC, and its associated 
reporting system, were supported both technically and by providing expertise and project 
management advice.
Specific groups with members from different units within the EMCDDA met to work on a 
project basis, for example Fonte and the Data warehouse. The groups worked together 
closely in order to ensure effective development of new applications.
(17)  40 calls for tender (8 Open procedure (OJ), 1 Restricted procedure following AMI, 5 Negotiated 
procedures — at least 3 candidates, 6 Negotiated procedures — at least 5 candidates, 20 Negotiated 
procedures — disp. Art. 126); 333 other contracting processes (27 grants, 74 order forms — Framework 
Contracts, 14 appointment letters and 218 low value contracts).
(18) 1 627 operations (1 542 payment orders/bank transfers, 85 recovery orders).
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ICT support for data management and dissemination
One of the objectives here for 2009 was to support core EMCDDA scientific activities, 
including applications for existing and new scientific fields. A project including members 
from several units in the Centre worked together to identify the requirements for choosing an 
application to manage bibliographic references in light of the EMCDDA’s aim to produce 
more scientific articles. This project also raised awareness on the need to plan further work 
on guidelines and work processes in this area. The increasing output in terms of scientific 
articles will require a sound reference management application, not only for producing the 
references, but also to manage and share these among colleagues as easily as possible. 
This work will continue in 2010.
A second ambition was to support EMCDDA networking and efficient communication to 
target audiences. Work started on a web content authoring review to establish publication 
automation within the content management application (CMA) and prepare architectural 
improvements. The publication wizard produced in 2009 makes the process of adding a 
new publication to the website far simpler.
Infrastructure and logistics
The move to new premises in 2009 was particularly relevant in light of the work 
programme’s objective to ensure premises and assets are managed according to best 
practice and to enhance protection and security of the buildings, assets and personnel. The 
whole move went smoothly and in accordance with the planned schedule. The procurements 
and operations to ensure the provision of services and supplies were carried out to the 
required level. Some processes for the management of infrastructure and logistics were 
further improved — for example an intranet based e-support application for I&L services 
was developed, as well as a booking system for service vehicles. The Interagency Greening 
Network Meeting was also organised and hosted by the EMCDDA in October 2009.
Statutory bodies and executive management
Introduction
The EMCDDA operates with three main management entities. The Management Board is the 
main decision-making body. It meets at least once a year and consists of one representative 
from each Member State of the European Union, two representatives from the European 
Commission and two representatives designated by the European Parliament. The Chairman 
of the Board is elected for a three-year period. The Executive Committee of the EMCDDA 
consists of the Chairman and the Vice-Chairman of the Management Board, one 
representative of the European Commission, one representative designated by the European 
Parliament and three representatives of Member States. The Executive Committee meets five 
to six weeks before each Management Board meeting to prepare for the latter in consultation 
with the Director. The Scientific Committee consists of up to fifteen well-known scientists 
appointed by the Management Board in view of their scientific excellence and their 
independence, following a publication of a call for expressions of interest in the Official 
Journal of the European Union (OJ). The members of the Scientific Committee are appointed 
in a personal capacity and give their opinions completely independently of the Member 
States and the Community Institutions and serve for a three-year period (renewable).
Management Board — main decisions
The Management Board met twice in 2009, from 1–2 July and from 3–4 December. At its 
July meeting, the Board:
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•  unanimously renewed the mandate of Wolfgang Götz as Director of the EMCDDA for a 
further term of five years, starting 1 May 2010;
•  adopted the new three-year strategy for the Centre and work programme for 2010–12;
•  decided, by derogation to the rules of procedure, that for the period from 1 July 2009 to 
30 June 2012, the number of members of the Budget Committee who represent Member 
States will be increased from three to four. This increase emphasises the importance of 
the said committee;
•  unanimously renewed Audronė Astrauskienė (Lithuania) for a second mandate, and 
elected Ralf Löfstedt (Sweden) and John Mc Cracken (United Kingdom) for a three-year 
term (from 1 July 2009 to 30 June 2012);
•  gave a favourable opinion on the final accounts of the EMCDDA for 2008 and endorsed 
the implementation of the international cooperation strategy.
At the board meeting in December, the key agenda items were the elections of a new Chair 
and Vice-Chair. João Goulão, Portuguese national drug coordinator and Head of the 
Institute for Drugs and Drug Addiction (IDT) — the national focal point in the EMCDDA’s 
Reitox network — was elected Chairman for the next three years. João Goulão has been 
member of the EMCDDA Board since 2005 and previously served on the agency’s Scientific 
Committee (1997–2002). He took over the position from Marcel Reimen (Luxembourg) 
whose mandate ended on 31 December 2009. EMCDDA Director Wolfgang Götz paid 
tribute to Mr Reimen for his ‘extraordinary contribution to the development of the agency 
since its very first steps’. Claude Gillard (Belgium), another founding member of the agency, 
was elected to the position of Vice-Chairman, and re-elected Chair of the Budget Committee 
by the Management Board.
Other actions taken by the board at the December meeting were:
•  approval of the agency’s 2010 budget and work programme, adopted unanimously and 
subject to the final opinion of the European Commission;
•  approval of the agency’s staff policy plan for the years 2011–13;
•  renewal of all members of the Scientific Committee for the next mandate from 2011 to 
2013 and extended the validity of the reserve list for the same period;
•  adoption of a Memorandum of Understanding formalising cooperation between the 
EMCDDA and the Ukraine, to be signed by the EMCDDA Director.
Finally, the new premises of the EMCDDA at Cais do Sodré were inaugurated in the 
presence of the Management Board and staff members on 1 July.
Meetings of EMCDDA Management Board
1–2 July Lisbon 39th Management Board meeting 
3–4 December Lisbon 40th Management Board meeting
Executive Committee — main decisions
At its meeting of 6 May, the Executive Committee commented on the draft documents for the 
Management Board meeting in July. The Director updated the Executive Committee on the 
situation concerning the move into the new premises at Cais do Sodré, and on the 
participation at the Scientific Conference organised by the EMCDDA starting the same day.
The Executive Committee took note, in restricted session, of the evaluation report on the 
performance of the Director by the Chair of the Management Board and by Francisco 
Fonseca-Morillo, representative of the European Commission. Further to the formal proposal 
by the College of Commissioners, the Executive Committee decided by unanimity, to 
recommend to the Management Board to renew the mandate of the EMCDDA Director 
Wolfgang Götz for a second term of five years starting 1 May 2010.
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Finally, the Executive Committee decided to nominate Matthew Hickman (Epidemiology, 
United Kingdom) from the reserve list as member of the Scientific Committee, in replacement 
of Jürgen Rehm.
The meeting of 7 October was preceded by an informal meeting of the Executive 
Committee with Roland Genson, Director for Justice and Home Affairs at the General 
Secretariat of the Council. The aim of the meeting was to share views on ways to strengthen 
future collaboration between the EMCDDA and the Council. The EMCDDA will seek to give 
a presentation of its Annual report at a Council of Ministers meeting, starting with the 
Belgian Presidency in autumn 2010.
Meetings of EMCDDA Executive Committee
6 May Lisbon Meeting of the Executive Committee
1 July Lisbon Meeting of the Executive Committee
7 October Lisbon Meeting of the Executive Committee
2 December Lisbon Meeting of the Executive Committee
Director — main activities
Institutional relations and non-EU countries
Throughout 2009, as the agency’s figurehead, the EMCDDA Director continued to work 
closely with European Commission colleagues and European and international partners, as 
well as non-EU countries. As regards the latter, the Director initiated and maintained contacts 
with high-level representatives from various countries (Australia, Canada, Croatia, Russia, 
Turkey, Ukraine and the US), as well as from IPA beneficiaries (Albania, Bosnia and 
Herzegovina, Croatia, the former Yugoslav Republic of Macedonia, Kosovo (under UN 
Security Council Resolution 1244/99), Montenegro, Serbia and Turkey), namely at the 
conference organised by the EMCDDA in November. Further to these meetings, he also 
hosted bilateral meetings with Ambassadors to Portugal from five non-EU countries, and also 
met with ambassadors from third countries who attended the reception offered by the 
EMCDDA to mark the International Day against Drug Abuse and Illicit Trafficking, on 26 June.
Relations with EU Member States
With regard to specific relations with the EMCDDA’s host nation Portugal, the meetings with 
the President of the Portuguese Republic, Aníbal Cavaco Silva and with the Portuguese 
Prime Minister, José Sócrates, in the framework of the EMCDDA’s fifteenth anniversary 
conference in May were fruitful. The Director also presented the EMCDDA’s 2009 Annual 
report to the Portuguese Parliament, met with Manual Pizarro, the Secretary of State for 
Health and made an intervention at the closing session of the 2009 National Congress of 
the Portuguese Drugs and Drug Addiction Institute.
Relations with EU Member State representatives included a visit to the agency by the United 
Kingdom’s Home Affairs Committee (House of Commons), French Senator Denis Badré, 
delegations from Sweden and Germany as well as Ambassadors to Portugal from various 
Member States.
European institutions (19)
In the framework of relations with the European Parliament, the main event in 2009 was the 
presentation of the Annual report to the Committee on Civil Liberties, Justice and Home 
(19)  For more details, see section ‘Strengthening cooperation and communication with partners’ in Part I, 
Chapter 2.
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Affairs prior to the report’s press launch. Following an invitation from Mr Paulo Sande, the 
head of the European Parliament’s Information office in Lisbon, Mr Götz also met with the 
newly elected Portuguese members of the European Parliament in Lisbon. Similarly, relations 
with the Council of the European Union in 2009 involved taking part in the National Drug 
Coordinators meting on 29–30 April in Prague, as well as the Horizontal Working Group 
organised during the Swedish Presidency.
During the audit of the agency’s 2008 annual accounts in May, the Director met with 
representatives from the Court of Auditors. He also met representatives of the Internal Audit 
Service who visited the EMCDDA from 15–19 June, in the framework of the IAS Audit Plan 
2008/2010 endorsed by the EMCDDA Executive Committee in 2008.
European agencies (20)
In 2009, the Director handed over the task of coordinator of the agencies network to EFSA 
and continued to be active in the Troika of Heads of Agencies (formed by the European 
Food Safety Authority (EFSA), the EMCDDA and the European Centre for Disease Prevention 
and Control (ECDC)).
Scientific Committee — main activities
The 2006 recast of the EMCDDA Regulation called for a new composition of the Scientific 
Committee, with 15 members and one member from Norway as observer, selected on the 
basis of their scientific excellence. The Scientific Committee members are guardians and 
advocates of the scientific integrity of the Centre. Their tasks include submitting opinions on 
the three-year and annual work programmes, to undertake risk assessments of new 
psychoactive substances, and to give opinions on any scientific matters concerning the 
Centre’s activity at the request of the Director or the Management Board.
The Scientific Committee met twice in 2009, from 15–16 June and 16–17 November. Each 
meeting was followed by a seminar given by one of its members for EMCDDA staff, to 
which the IDT was also invited. The Chair of the Scientific Committee participated as 
observer in the Management Board meetings. There was one change to the Committee 
(Matthew Hickman, University of Bristol replaced Jürgen Rehm from the Technical University 
of Dresden). The Management Board in December reappointed all members of the 
Committee for the 2011–13 period.
The Scientific Committee made proposals to increase the scientific quality of the EMCDDA’s 
work, using the Annual report as point of reference, and also encouraged the EMCDDA to 
increase scientific publishing by both staff and associated experts. On two occasions, 
Scientific Committee members tutored seminars on scientific publishing for EMCDDA staff. 
Similarly, the Committee gave positive formal opinions on the 2010 and 2010–12 work 
programmes. Members reviewed the Annual report, Selected issues and commented on 
other publications and documents, as required. Almost all members participated as speakers 
or chairs for the EMCDDA’s fifteenth anniversary conference. Individual members also 
contributed as authors and peer reviewers on the Harm reduction monograph (2010 
production), the Drugs in focus on neurobiological research on drugs and took part in 
expert meetings on ‘Spice’, public expenditure and drug-related deaths.
Meetings of the Scientific Committee
15–16 June Lisbon 30th Scientific Committee meeting
16–17 November Lisbon 31st Scientific Committee meeting
(20) Ibid.
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Chapter 1 
Characteristics and nature of EMCDDA management 
and internal control systems
In accordance with the financial regulation applicable to the EMCDDA, which transposes 
integrally the text of the Framework Financial Regulation No 2343/2002 (21), the EMCDDA 
has set its internal procedures for budget execution and internal control, while defining and 
implementing a partially decentralised management model.
As a consequence, both operational and financial decisions required for the implementation 
of the Centre’s work programme and budget have been delegated to the heads of unit. The 
Administration unit provides support to managers for budgetary and financial management 
as well as overall internal planning and monitoring.
These procedures have been codified and all of the EMCDDA’s heads of unit/deputy 
authorised officers have received specific training and information on their role, duties and 
liability, in accordance with the provisions of the financial and staff regulations.
The key actors and steps of the EMCDDA procedures for budget execution can be 
summarised as follows:
•  Project manager: initiative and operational input for the administrative and financial 
operations in relation to project implementation (technical specifications for tendering 
procedures, cost estimate, ‘certified correct’ for payments)
•  Financial management team: financial and contractual support officers help prepare the 
administrative and contracting supporting documents with the input of the project 
manager concerned
•  Planning and evaluation team: checks consistency with work programme and budget
•  Financial management team: ABAC initiating officers carry-out operations in the 
EMCDDA’s ABAC electronic management and accounting system, prior to the decision of 
the authorising officer
•  Directorate: the verifying officer carries-out ex ante checks
•  Head of unit: gives authorisation of budgetary and legal operations, acting as deputy 
authorising officer by delegation (from the Director as EMCDDA authorising officer) for 
the execution of the tasks/activities of his/her unit, within the limits of the adopted 
EMCDDA annual work programme and budget
•  Accountant: makes the required financial transactions.
The procedures presented above are consistent with the EMCDDA’s project-based working 
methods aimed at integrating activities and resources management, in accordance with the 
activity-based management/activity-based budgeting principles. In this context, the Centre 
has established procedures for planning, monitoring and reporting, with a clear indication 
of the actors involved, their roles and responsibilities.
Following the adoption of the new ‘Operating framework for the Reitox system’ in January 
2003, a new grant agreement model has been introduced for the annual co-financing of 
activities by the Reitox national focal points. This agreement requires that an external audit 
be carried out each year by an independent body or expert in order to certify that the 
financial documents submitted to the EMCDDA comply with the financial provisions of the 
agreement, that the costs declared are the actual costs, and that all receipts have been 
declared.
(21) Amended by Commission Regulation (EC, EURATOM) No 652/2008.
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The EMCDDA is currently subject to the following checks and controls:
•  External audit by the European Court of Auditors (twice a year)
•  External audit for specific projects (PHARE, CARDS, etc.)
•  Discharge by the European Parliament (once a year)
•  Internal audit by the European Commission’s Internal Audit Service (once a year)
•  Opinion of the European Commission’s services on the agency’s staff policy plan (once a 
year)
•  External periodical evaluation (set as every six years in the EMCDDA founding regulation)
•  Agreement by the European Commission on implementing rules to Staff regulations (for 
each rule)
•  The European Data Protection Supervisor for compliance with Regulation 45/2001 (by 
prior notification and upon complaint)
•  The European Anti-Fraud Office (upon complaint)
•  The Ombudsman (upon complaint)
•  Civil Service Tribunal — Court of First Instance — European Court of Justice (upon 
complaint).
Key features of the EMCDDA’s partially decentralised management model
Actors/level of operations Role/operations
Decentralised level (operational and 
technical units)
Operational initiative/input and operational and 
financial decisions by delegation in order to 
implement the work programme (WP) and budget
Central level (Directorate and Administration 
unit)
Co-ordination and management of executive 
planning, monitoring, reporting and assessment of 
the implementation of the WP and budget
Administrative and financial support, 
management and control of implementation
Key actors and processes for the execution of the EMCDDA WP and budget
Level of operations Actors Role/operations
Decentralised level 
(operational and 
technical units)
Project manager and 
head of unit concerned 
Initiative and operational input for the 
operations required to implement projects 
Central level 
(Administration unit)
Planning and evaluation 
team
Checks consistence of operations with 
adopted WP and budget. Budgetary 
appropriations to be committed are set aside
Human resources 
management team
Defines rights and checks compliance with 
staff regulations for staff-related management 
and expenditure 
Financial management 
team
Prepares the required administrative and 
legal supporting documents and controls 
compliance with applicable regulations. 
Processes the required ABAC operations
Central level 
(Directorate)
Verifying officer Ex ante verification
Decentralised level 
(operational and 
technical units)
Head of unit/deputy 
authorising officer 
Authorise budgetary and legal commitments 
and payments (and recovery orders)
Central level 
(Administration unit)
Accounting officer Executes and records payments and recovery 
orders
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Chapter 2 
Assessment and improvement of management and 
internal control systems
In 2009, following-up on observations and recommendations expressed by the European 
Court of Auditors and the EU Budget Authority and audits by the Internal Audit Service of 
the European Commission (IAS), the EMCDDA implemented some measures to improve its 
management and internal control systems as follows:
Measures relating to observations resulting from the IAS’ 2007 follow-up audit:
•  A new EMCDDA staff appraisal system was implemented including adequate information 
and guidance to reporting officers and jobholders
•  The promotion exercise was carried out and finalised in accordance with the provisions 
laid down in the Management Board decisions on staff promotion and reclassification
•  The 2010 work programme, as submitted to the EMCDDA’s Management Board in 
December 2009 lists the main potential risks for its implementation and identifies the 
mitigating measures taken or to be taken.
Measures relating to observations resulting from IAS’ 2008 audit on the EMCDDA’s 
preparedness for the move:
•  Quality control of the new location
•  Precautions against damages emerging from flooding
•  Business continuity plan
•  Timely execution of necessary ICT procurement operations
•  Allocation of adequate budget resources
•  Adequate investment in necessary equipment
•  Effective document handling policy
•  Proper planning of the move and protection of assets.
Measures relating to observations resulting from IAS’ 2009 audit on management of grants 
for the Reitox national focal points:
•  Financial planning
•  More structured evaluation of grant applications
•  More rational and consistent model grant agreements, pursuant to the model adopted by 
the Commission’s services
•  Clear guidelines and process for suspension of deadlines for payment, in accordance 
with the relevant financial rules
•  Quality assessment procedure.
Measures aimed at improving the management of the general ledger accounts relating to 
observations resulting from Court of Auditors’ 2008 audit:
•  Improved monthly reconciliation process through reports from the Data warehouse and 
SAP
•  Regular controls on non-budgetary accounts through the reporting tools (Data warehouse 
and SAP)
•  Development of a VAT reconciliation report from the data warehouse in order to match all 
amounts of VAT to be refunded by the Portuguese authorities
•  New ageing balance for the management and follow-up of recovery orders
•  New income structure for 2010.
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Chapter 3 
Declaration of assurance by authorising officer
I, the undersigned, Director of the European Monitoring Centre on Drugs and Drugs 
Addiction
In my capacity as Authorising Officer
•  Declare that the information contained in this report gives a true and fair view (22).
•  State that I have reasonable assurance that the resources assigned to the activities 
described in this report have been used for their intended purpose and in accordance 
with the principles of sound financial management, and that the control procedures put in 
place give the necessary guarantees concerning the legality and regularity of the 
underlying transactions.
•  This reasonable assurance is based on my own judgment and on the information at my 
disposal, such as the results of the self-assessment, ex post controls, the work of the 
internal audit capability, the observations of the Internal Audit Service and the lessons 
learnt from the reports of the Court of Auditors for years prior to the year of this 
declaration.
•  Confirm that I am not aware of anything not reported here which could harm the interests 
of the institution.
Done in Lisbon, on 1 June 2010
Wolfgang götz 
Director
(22)  True and fair in this context means a reliable, complete and correct view on the state of affairs in the 
service.
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Annex 1 
Objectives as defined in the EMCDDA’s 2009 Work 
programme
Core business
1. Consolidate monitoring and reporting activities
Key epidemiological indicators
Objective 1.1 To improve and strengthen the implementation and coverage of the key 
epidemiological indicators in the Member States on the basis of the work done 
in 2008 by clarifying and updating standards and criteria
Objective 1.2 To review and update, where necessary, the definition and data collection 
requirements of the key epidemiological indicators to ensure relevance and 
appropriateness
Monitoring and reporting in support of Council decision on new psychoactive substances  
(2005/387/JHA)
Objective 1.3 To provide efficient support to the areas of work detailed in the Council 
decision on the information exchange, risk assessment and control of new 
psychoactive substances (2005/387/JHA) that fall within the remit of the 
EMCDDA, such as the early warning system and risk assessment exercises
Annual reporting
Objective 1.4 To continue to improve the quality of the Annual report and the accessibility of 
its findings
Objective 1.5 To improve the utility of the Statistical bulletin by rationalising the presentation 
of data
Objective 1.6 To improve the content, presentation and timeliness of the Country overviews
Objective 1.7 To further develop the EMCDDA’s quality assurance policy for data submitted 
and internal control checks
Revision of reporting tools
Objective 1.8 To revise national reporting tools in line with ongoing discussions with national 
focal points (continuation of work launched in 2007)
Objective 1.9 To develop an integrated approach to monitoring drug treatment and harm 
reduction
Objective 1.10 To have a better framework for developing tools and introducing data collection 
approaches in the areas of crime and drug supply
Fonte/Data management
Objective 1.11 To assure a successful first complete year of Fonte reporting and validation by 
providing efficient maintenance, support and improved functions and data 
management procedures
Objective 1.12 To further develop, expand and make the Fonte application more accessible 
and useful to its users
Objective 1.13 To consolidate EMCDDA knowledge and expertise by knowledge sharing and 
data streamlining
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Network management and capacity building
Objective 1.14 To improve the capacity of the national focal points to fulfil EMCDDA tasks, 
including the implementation of the five key epidemiological indicators and 
other core data and to develop the training materials
Objective 1.15 To improve data collection network management
Objective 1.16 To further develop networking activities and partnerships in the research area, 
in particular through the Scientific Committee
Developmental and conceptual activities
Objective 1.17 To continue to improve the focus, scope and appropriateness of EMCDDA data 
collection and reporting tools and mechanisms
Objective 1.18 To review annual reporting infrastructure in the context of information needs 
arising from the EU action plan
2. Enhance analysis of data
2.1. Key epidemiological indicators
Objective 2.1 To improve analysis of key epidemiological indicator data
Objective 2.2 To gain greater value from data through cross-indicator analysis
Objective 2.3 To conduct focused analysis on issues of particular policy relevance
2.2. Analysis of patterns and trends
Objective 2.4 To ensure European level analyses of patterns and trends are available and up 
to date
Objective 2.5 To develop an improved statistical approach for analysing long- and medium-
term trends in drug use in Europe based on synthesising data from different 
sources
Objective 2.6 To increase understanding of polydrug use in mortality and other aspects 
related to drug use
Objective 2.7 To better link the analysis of demand- and supply-side data
2.3. Analytical focus on responses and best practice
Objective 2.8 To better report on best practice in different fields of intervention
Objective 2.9 To improve analysis of the extent to which European responses meet estimated 
needs
Objective 2.10 To further develop the economic analysis of drug issues
3. Communicate more effectively with key audiences
3.1. High-quality, timely and accessible products
Objective 3.1 To publish high-quality and timely products in line with the targets committed to 
in the 2007–09 work programme
Objective 3.2 To improve the relevance and accessibility of products
Objective 3.3 To further improve the quality of products and efficiency of the editorial process
3.2. Dialogue with stakeholders and partners
Objective 3.4 To intensify dialogue with stakeholders and partners
Objective 3.5 To facilitate access to drug related science and research and promote exchange 
with the scientific community
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Objective 3.6 To better facilitate the dissemination of good practice and sharing of experience 
with drug professionals
Objective 3.7 To better represent developments and dialogue of civil society and the drugs 
issue
3.3. Cohesive representation and communication
Objective 3.8 To promote a cohesive and shared approach to representation activities across 
the EMCDDA
3.4. ‘EMCDDA, your reference point on drugs in Europe’
Objective 3.9 To enhance the EMCDDA’s reputation and recognition as the European central 
reference point and authoritative information source in the drugs field
4. Strengthening cooperation and communication with partners
4.1. European Commission services
Objective CO.1 To collaborate actively with the European Commission services involved in the 
field of drugs
4.2. Cooperation and collaboration with European and international partners
Objective CO.2 To actively collaborate with other EU agencies in the field of drugs, including 
the action on new drugs
Objective CO.3 To strengthen cooperation with international organisations and agencies on 
cross-cutting drug-related issues
4.3. Scientific community and professional networks
Objective CO.4 To promote scientific partnerships and professional networking
4.4. Technical assistance to candidate and potential candidate countries
Objective CO.5 To prepare candidate and potential candidate countries to the EU for their 
participation in the EMCDDA
4.5. International cooperation with non-EU countries
Objective CO.6 To coordinate, facilitate and support cooperation between the EMCDDA and 
non-EU countries
Support activities
1. Administration and support
1.1. Planning, reporting and legal matters
Objective SA.1 To improve efficiency, effectiveness and transparency in planning, reporting and 
monitoring processes
1.2. Financial management
Objective SA.2 To implement and assure appropriate processes and procedures for financial 
management and control
1.3. Accountancy
Objective SA.3 To ensure that accounting data and related information used for preparing 
EMCDDA accounts and financial statements are accurate and timely through the 
application of a new integrated accounting and payment system
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1.4. Human resources management
Objective SA.4 To implement and monitor rules, procedures and tools for managing and 
developing human resources at the EMCDDA
1.5. ICT developments for improving organisational efficiency
Objective SA.5 To provide ICT systems that help to enhance EMCDDA organisation, productivity 
and resource allocation
1.6. ICT support for data management and dissemination
Objective SA.6 To support core EMCDDA scientific activities including ICT applications for 
existing and new scientific fields
Objective SA.7 To support EMCDDA networking and efficient communication to target 
audiences
1.7. Infrastructure and logistics
Objective SA.8 To ensure that the EMCDDA premises and assets are managed according to 
best practice within the business; to maintain and enhance protection and 
security of EMCDDA buildings, assets and personnel including a smooth 
transition after the move to the new building; and to maintain smooth provision 
of transportation, mail and reception services
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Annex 3 
Breakdown of EMCDDA staff as of 31 December 2009
Total EMCDDA staff (100). Contract agents (CA), Temporary agents (TA), Officials
Categories
Grades Officials
Gender
TA
Gender
Male Female Male Female
AD
15  1  1
14
13  2  1  1
12  1 1   4  3  1
11  4 3 1  6  3  3
10  3  2  1
 9  7  4  3
 8  1 1  3  2  1
 7  2  2
 6 13  5  8
 5
47 Subtotal AD  6 5 1 41 21 20
AST
11  1 1
10
 9  1  1
 8  1 1  2  1  1
 7  1 1  1  1
 6  1 1  2  2
 5  1 1  1  1
 4  1 1 13  5  8
 3  1 1  3  2  1
 2  1  1
 1
31 Subtotal AST  7 2 5 24 12 12
TOTAL 13 7 6 65 33 32
Function group
Gender Total 
EMCDDA 
staff
Gender
Male Female Male Female
Contract 
agents
IV 100 48 52
III  8 4  4 % 48 52
II 11 1 10
I  3 3
Total CA 22 8 14 Administrator = AD Assistant = AST
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Outputs
Conference
Conference Learning from the past, looking to the future: identifying Europe s´ information 
needs for effective drug policy
Conference materials including programme, presentations, and press information available 
online: http://www.emcdda.europa.eu/events/2009/conference
Conference proceedings: Identifying Europe’s information needs for effective drug policy, 
EMCDDA, Lisbon, December 2009.
Cat. No: TD-30-09-181-EN-C
http://www.emcdda.europa.eu/html.cfm/index95271EN.html
22 posters produced in-house:
– Annual report: the state of the drugs problem in Europe
– Monitoring new drugs — more then 10 years of multi-agency cooperation
– Drug users in European prisons — a population with specific healthcare needs
– Our print and online products
–  Comparing problem drug users in treatment with estimates of problem drug use — 
epidemiological indicators of treatment needed?
– Best practice portal
– Tailoring information to client needs
–  Surveillance of injecting drug use and drug-related infectious diseases in the European 
Union
– Public expenditure: state of the art and country experiences
– Your reference point on drugs in Europe
– Monitoring drug-related mortality in Europe: a key epidemiological indicator for action
– Trends and availability of responses to drug use in recreational settings in Europe
– Reitox — our partners in the Member States
– Representative surveys: key indicator to represent drug use in the general population
– Monitoring Europe’s drug situation: tasks and organisation
– International cooperation
– Emerging drug trends in Europe
–  Treatment demand indicator (TDI) — implementation and recent developments in patterns 
of drug use among treatment clients
– National drug-related research in Europe
– The transit of cocaine via West Africa to Europe
– The supply of heroin to Europe
– Opioid substitution treatment in Europe — trends and availability
All available in PDF format online:
http://www.emcdda.europa.eu/events/2009/conference#posters
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EMCDDA scientific outputs/products, 2009
Annual reporting
2009 Annual report: the state of the drugs problem in Europe, EMCDDA, Lisbon, November 
2009.
A yearly overview of the drug phenomenon in Europe.
Available in 23 languages — all EU official languages (except Maltese and Gaelic), plus 
Norwegian and Turkish.
Cat. No: TD-AC-09-001-BG/CS/DA/DE/EL/EN/ES/ET/FI/FR/HU/IT/LT/LV/NL/NO/PL/PT/
RO/SK/SL/SV/TR-C
http://www.emcdda.europa.eu/publications/annual-report/2009
Also presented online in EN:
http://www.emcdda.europa.eu/situation/analysis
Selected issues 2009
Drug offences: sentencing and other outcomes, EMCDDA, Lisbon, November 2009.
Cat. No: TD-SI-09-001-EN-C
http://www.emcdda.europa.eu/publications/selected-issues/sentencing-statistics
Accompanied by a multilingual summary available in 23 languages:
http://www.emcdda.europa.eu/html.cfm/index93231EN.html
Polydrug use: patterns and responses, EMCDDA, Lisbon, November 2009.
Cat. No: TD-SI-09-002-EN-C
http://www.emcdda.europa.eu/publications/selected-issues/polydrug-use
Accompanied by a multilingual summary available in 23 languages:
http://www.emcdda.europa.eu/html.cfm/index93218EN.html
Statistical bulletin (web-based)
The epidemiological basis on which the Annual report is based, with over 350 tables and 
100 graphics collated by the EMCDDA from the information submitted by the network of 
Reitox national focal points.
Available as a website in EN: http://www.emcdda.europa.eu/stats09
Country overviews
Summaries of the national drug situation, key statistics and a barometer showing the drug 
use prevalence position in each country.
http://www.emcdda.europa.eu/publications/country-overviews
Country overviews 2009 (Balkans)
Summaries of the national drug situation showing the drug use prevalence position in five 
countries: Albania, Bosnia and Herzegovina, FYROM, Montenegro, Serbia
Available online and in national language:
http://www.emcdda.europa.eu/publications/country-overviews
Also available as printed publications in EN and national languages.
General report of activities
General report of activities 2008, EMCDDA, Lisbon, June 2009.
A detailed progress report of the EMCDDA’s activities over a 12-month period.
http://www.emcdda.europa.eu/html.cfm/index80986EN.html
Annual accounts 2008, EMCDDA, Lisbon, August 2009.
http://www.emcdda.europa.eu/html.cfm/index81990EN.html
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Outputs linked to the implementation of the Council Decision on new 
psychoactive substances (2005/387/JHA)
EMCDDA–Europol cooperation: Joint publications on illicit drugs, EMCDDA, Europol, Lisbon, 
April 2009.
Cat. No: TD-80-09-633-EN-D
This brochure presents the EMCDDA–Europol publication series on illicit drugs.
http://www.emcdda.europa.eu/publications/illicit-drugs
EMCDDA Monographs
Addiction neurobiology: ethical and social implications, EMCDDA, Lisbon, June 2009.
Cat. No: TD-AL-09-009-EN-C
http://www.emcdda.europa.eu/publications/monographs/neurobiology
EMCDDA Insights
Internet-based drug treatment interventions, EMCDDA, Lisbon, July 2009.
Cat. No: TD-XD-09-010-EN-C
http://www.emcdda.europa.eu/html.cfm/index78701EN.html
Drug profiles
Objective and scientifically sound descriptions of controlled drugs.
Three published in 2009: BZP and other piperazines, Synthetic cannabinoids and ‘Spice’, 
Barbiturates. All others were updated. Available as a website in DE, EN and FR.
http://www.emcdda.europa.eu/publications/drug-profiles
Drugs in focus policy briefings
Drugs in focus 19: Neurobiological research on drugs: ethical and policy implications, 
EMCDDA, Lisbon, June 2009.
Published in all official EU languages plus Norwegian and Turkish.
Cat. No: TD-AD-09-001-BG/CS/DA/DE/EL/EN/ES/ET/FI/FR/GA/HU/IT/LT/LV/MT/NL/
NO/PL/PT/RO/SK/SL/SV/TR-C
http://www.emcdda.europa.eu/html.cfm/index81453EN.html
Drugs in focus 20: Responding to drug driving in Europe, EMCDDA, Lisbon, September 2009.
Published in all official EU languages plus Norwegian and Turkish.
Cat. No: TD-AD-09-002-BG/CS/DA/DE/EL/EN/ES/ET/FI/FR/GA/HU/IT/LT/LV/MT/NL/
NO/PL/PT/RO/SK/SL/SV/TR-C
http://www.emcdda.europa.eu/publications/drugs-in-focus/driving
Thematic papers
Preventing later substance use disorders in at-risk children and adolescents, EMCDDA, 
Lisbon, February 2009.
Cat. No: TD-XA-09-001-EN-N
http://www.emcdda.europa.eu/publications/thematic-papers/indicated-prevention
Women’s voices — experiences and perceptions of women facing drug problems, 
EMCDDA, Lisbon, May 2009.
http://www.emcdda.europa.eu/publications/thematic-papers/womens-voices
Drug use: an overview of general population surveys in Europe,
EMCDDA, Lisbon, April 2009.
Cat. No: TD-XA-09-003-EN-C
http://www.emcdda.europa.eu/publications/thematic-papers/gps
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Understanding the ‘Spice’ phenomenon, EMCDDA, Lisbon, November 2009.
http://www.emcdda.europa.eu/publications/thematic-papers/spice
Drugnet Europe
Drugnet Europe
The EMCDDA’s quarterly newsletter. Provides regular information on the Agency’s activities 
to a broad readership. Four editions in 2009 (65, 66, 67, 68). Available in EN.
http://www.emcdda.europa.eu/publications/drugnet
Also available as a website:
http://www.emcdda.europa.eu/publications/drugnet/online
EMCDDA overview brochure, EMCDDA, Lisbon, November 2009.
Cat. No: TD-30-08-565-BG/CS/DA/DE/EL/EN/ES/ET/FI/FR/HR/
HU/IT/LT/LV/NL/NO/PL/PT/RO/RU/SK/SL/SV/TR-C
http://www.emcdda.europa.eu/publications/brochures/overview
Annual report bookmark, EMCDDA, Lisbon, October 2009.
http://www.emcdda.europa.eu/html.cfm/index92819EN.html
Media products
News releases
12 news releases
No 1 — European school survey project on alcohol and other drugs (ESPAD)
‘ESPAD, a crucial window onto adolescent substance use’
(26.3.2009) EN
No 2 — Identifying Europe’s information needs for effective drug policy
EMCDDA to celebrate 15 years of drug monitoring with international conference
(28.4.2009) DE/EN/FR/PT
No 3 — EMCDDA 15 years: conference highlights
(8.5.2009) DE/EN/FR/PT
No 4 — 26 June: International day against drug abuse and illicit trafficking
Advances in brain research throw light on addiction
(24.6.2009) DE/EN/FR/PT
No 5 — Second term for Director of EU drugs agency
EMCDDA Management Board renews mandate of Wolfgang Götz
(1.7.2009) DE/EN/FR/PT
No 6 — Republic of Croatia to become member of EMCDDA
Croatian Deputy Prime Minister and dignitaries pay study visit to EU drugs agency
(21.8.2009) EN/PT/HR
No 7 — Latest on the drugs problem across Europe
Annual report 2009 from the EU drugs agency
(21.10.2009) BG/CS/DA/DE/EL/EN/ES/ET/FI/FR/HU/IT/LT/LV/NL/NO/PL/PT/RO/SK/SL/
SV/TR
No 8 — Annual report 2009: highlights
(5.11.2009) BG/CS/DA/DE/EL/EN/ES/ET/FI/FR/HU/IT/LT/LV/NL/NO/PL/PT/RO/SK/SL/
SV/TR
No 9 — New drugs: difficulties of ‘hitting a moving target’
Market innovation and sophistication challenge drug policies
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(5.11.2009) BG/CS/DA/DE/EL/EN/ES/ET/FI/FR/HU/IT/LT/LV/NL/NO/PL/PT/RO/SK/SL/
SV/TR
No 10 — ‘Community agencies: partners in accession’
Candidate and potential candidate countries to the EU meet Community agencies in 
Portugal
(20.11.2009) EN/PT/HR/TR/MK
No 11 — ‘Community agencies: partners in accession’
Role of Community agencies in EU enlargement process reinforced
(27.11.2009) EN
No 12 — ‘EU drugs agency Management Board elections’
Board elects Portuguese member João Goulão as new EMCDDA Chairman
(3.12.2009) EN/PT
Message from Wolfgang Götz, director of the EMCDDA
(5.11.2009) BG/CS/DA/DE/EL/EN/ES/ET/FI/FR/HU/IT/LT/LV/NL/NO/PL/PT/RO/SK/SL/
SV/TR
The 2009 headlines and key facts PowerPoint presentation
(5.11.2009) BG/CS/DA/DE/EL/EN/ES/ET/FI/FR/HU/IT/LT/LV/NL/NO/PL/PT/RO/SK/SL/
SV/TR
MP3 files of comments from the EMCDDA Director on the Annual report 2009
http://www.emcdda.europa.eu/about/press/audio
Fact sheets
6 fact sheets available only in EN
Fact sheet 1: Preventing the development of dependence
(20.2.2009) New EMCDDA thematic paper on indicated prevention
Fact sheet 2: 8 March: International Women’s Day
(5.3.2009) Women’s voices — experiences and perceptions of women facing drug 
problems
Fact sheet 3: EMCDDA–Europol cooperation 2009–12
(16.3.2009) EMCDDA and Europol step up cooperation on drugs and crime
Fact sheet 4: New series of publications launched today
(13.7.2009) EMCDDA and Europol release joint report on methamphetamine
Fact sheet 5: Notification — new contact details
(31.8.2009) EU drugs agency, EMCDDA, moves to new premises
Fact sheet 6: Responding to drug driving in Europe
(18.9.2009) New EMCDDA policy briefing underlines need for enforceable and evidence-
based laws
Online tools and web-based resources
EMCDDA public website
The gateway to drug information in Europe.
http://www.emcdda.europa.eu
Thematic web pages
Collection of available EMCDDA resources on a particular topic.
Neuroscience
http://www.emcdda.europa.eu/themes/neuroscience
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Young people
http://www.emcdda.europa.eu/themes/young-people
Drug-related research
http://www.emcdda.europa.eu/themes/research 
Evaluation Instruments Bank (EIB)
An online archive of freely available instruments for evaluating drug-related interventions.
http://www.emcdda.europa.eu/eib
Publications database (version 2.0)
A full archive of all publications produced by the agency.
http://www.emcdda.europa.eu/publications
Best practice portal
A resource for professionals, policymakers and researchers in the areas of drug-related 
prevention, treatment, harm reduction and social reintegration.
http://www.emcdda.europa.eu/best-practice
Scientific Committee website
http://www.emcdda.europa.eu/html.cfm/index6819EN.html
Scientific Committee extranet (restricted)
IPA conference
Conference materials available online:
http://www.emcdda.europa.eu/events/ipa-conference
Joint publications and contribution to partners’ reports
Summary of the 2007 ESPAD report, EMCDDA, ESPAD, Lisbon, March 2009.
Available in 23 languages — all EU official languages (except Maltese and Gaelic), plus 
Norwegian and Turkish.
Cat. No: TD-80-09-567-BG/CS/DA/DE/EL/EN/ES/ET/FI/FR/HU/IT/LT/LV/NL/NO/PL/PT/
RO/SK/SL/SV/TR-C
http://www.emcdda.europa.eu/publications/espad
Methamphetamine: a European Union perspective in the global context, EMCDDA, Europol, 
Lisbon, July 2009.
Cat. No: TD-AN-09-001-EN-C
http://www.emcdda.europa.eu/html.cfm/index82068EN.html
EMCDDA technical reports, papers, reviews and articles
Bravo, M. J., Royuela, L., De La Fuente, L., Brugal, M.T., Barrio, G., Domingo-Salvany, A. 
(2009), ‘Use of supervised injection facilities and injection risk behaviours among young 
drug injectors‘, Addiction Apr; 104(4), pp. 614–9.
Costa Storti, C., De Grauwe, P. (2009), ‘The cocaine and heroin markets in the era of 
globalisation and drug reduction policies‘, International Journal of Drug Policy, 20 pp. 488–496.
Costa Storti, C., De Grauwe, P. (2009), ‘Globalization and the price decline of illicit drugs‘, 
International Journal of Drug Policy, 20 (1), pp. 48–61.
Gyarmathy, V.A., Giraudon, I., Hedrich, D., Montanari, L., Guarita, B., Wiessing, L. (2009), 
‘Drug use and pregnancy — challenges for public health‘, Eurosurveillance, Mar 5; 14(9), 
pp. 33-6.
Gyarmathy, V.A., Li, N., Tobin, K.E., Hoffman, I.F., Sokolov, N., Levchenko, J., Batluk, J., 
Kozlov, A.A., Kozlov, A.P., Latkin, C.A. (2009), ‘Correlates of unsafe injecting among injecting 
drug users in St Petersburg, Russia‘, European Addiction Research; 15: pp. 163–170.
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Gyarmathy, V.A., Li, N., Tobin, K.E., Hoffman, I.F., Sokolov, N., Levchenko, J., Batluk, J., 
Kozlov, A.A., Kozlov, A.P., Latkin, C.A. (2009), ‘Injecting equipment sharing in Russian drug 
injecting dyads‘, AIDS and Behavior, 13 February.
Gyarmathy, V.A., Neaigus, A., Mitchell, M.M., Ujhelyi, E. (2009), ‘The association of 
syringe type and syringe cleaning with HCV infection among IDUs in Budapest, Hungary‘, 
Drug and Alcohol Dependence. 1 March; 100(3): pp. 240–7. Epub 2008, 5 December.
Gyarmathy, V.A., Neaigus, A., Ujhelyi, E. (2009), ‘Vulnerability to drug-related infections 
and co-infections among injecting drug users in Budapest, Hungary‘,  European Journal of 
Public Health, June; 19(3): pp. 260–5. Epub 2009, 17 February.
Hillebrand, J., Burkhart, G. (2009), ‘Bridging the science-practice gap in drug demand 
reduction: A European perspective‘, Drugs: Education, Prevention and Policy 16(6): pp. 561–571.
Hughes, B., Blidaru, T. (2009), ‘Legal responses to new psychoactive substances in Europe‘, 
http://eldd.emcdda.europa.eu/html.cfm/index5175EN.html
Nilson, M., Lopez, D., Robertson, K., Martel, C., Simon, R., Griffiths, P. (2009), ‘The 
European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) — the information 
hub on drugs in Europe‘, Narkologia.
Olszewski, D., Matias, J., Monshouwer, K. and Kokkevi, A. (2009), ‘Polydrug use among 
15- to 16-year-olds: Similarities and differences in Europe‘, Drugs: Education, Prevention and 
Policy, 5, pp. 1–16.
Olszewski, D., ‘Sexual assaults facilitated by drugs or alcohol‘ (2009), Drugs: Education, 
Prevention and Policy, Volume 16:1, pp. 39–52.
Pirona, A., Hedrich, D. (2009), ‘Treatment of cocaine dependence: an update and 
innovations‘, Pharmagazine, 10(1); p. 3.
Pirona, A., Morgan, M. (2009), ‘An investigation of the subacute effects of ecstasy on 
neuropsychological performance, sleep and mood in regular ecstasy users‘, Journal of 
Psychopharmacology, 7 April. 
Prieto, L. (2009) ‘El gasto público relacionado con la droga en Europa‘, Revista Española 
de Drogodependencias,  34(3); pp. 260–271.
Royuela, L., Laniel, L., Vicente, J., Matias, J., Carpentier, C. (2009), ‘Oferta y demanda de 
cocaína en Europa y España’, Publicación de las V Jornadas del Observatorio 
Drogodependencias de Castilla-La Mancha, FISCAM 2008. Observatorio de 
Drogodependencias de Castilla-La Mancha, 2009 November (5): pp. 47–69.
Simon, R., Burkhart, G. (2009), ‘Drogenkonsum und Suchtprävention in Europa: eine 
Situationsbeschreibung der Europäischer Beobachtungsstelle für Drogen und Drogensucht 
(EBDD)‘, Kinder– und Jugendschutz in Wissenschaft und Praxis, 54; pp. 14–18.
Simon, R., Nilson, M., Griffiths, P. (2009), ‘15 Jahre EBDD —15 Jahre Drogenmonitoring in 
Europa: Eine Konferenz zwischen Wissenschaft und Politik‘, Sucht Volume 55, p. 135.
Vicente, J., Giraudon, I., Matias, J., Hedrich, D., Wiessing, L. (2009), ‘Rebound of overdose 
mortality in the European Union 2003–2005: Findings from the 2008 EMCDDA Annual 
report‘, Eurosurveillance, Volume 14, Issue 2.
Vigna-Taglianti, F., Vadrucci, S., Faggiano, F., Burkhart, G., Siliquini, R., Galanti, M.R., and 
the EU-Dap Study Group (2009), ‘Is universal prevention against youths’ substance misuse 
really universal? Gender-specific effects in the EU-Dap school-based prevention trial‘, Journal 
of Epidemiology and Community Health; 63; pp. 722–728.
Wiessing, L., Olszewski, D., Klempová, D., Vicente, J., Griffiths, P. (2009), ‘EMCDDA Annual 
report 2009: cocaine and heroin maintain firm hold on Europe’s drug scene‘, Eurosurveillance, 
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14(46): pii=19410. Available online: http://www.eurosurveillance.org/ViewArticle.
aspx?ArticleId=19410
Wiessing, L., Likatavičius, G., Klempová, D., Hedrich, D., Nardone, A. and Griffiths, P. 
(2009), ‘Associations between availability and coverage of HIV-prevention measures and 
subsequent incidence of diagnosed HIV infection among injection drug users‘, American 
Journal of Public Health, Volume 99, No 6, p. 1049.
Key events, visits, participation in conferences and technical 
meetings, 2009
Date Venue Title
Scientific and institutional coordination
13–14 January Brussels Inter Service Group, HDG and Troika Ukraine
20 January Brussels Inter Service Group — European Alliance on Drugs
26–27 January Krakow III Meeting of the Inter-Agency Group (Pompidou Group)
3–4 February Stockholm ECDC Advisory Group for Dublin Declaration on Partnership to fight AIDS
4–5 February Brussels Horizontal Drugs Group meeting and Troika Central Asia States and Afghanistan
9–10 February Lisbon EMCDDA/JLS meeting
10–11 February The Hague EMCDDA delegation visit to Europol
11–12 February The Hague EMCDDA delegation meeting with the Europol Drugs Unit
24–25 February Brussels ISG meeting and Horizontal Working Party on Drugs
2–4 March Vienna Third Annual Conference of the International Society for the Study of Drug Policy 
(ISSDP)
3–4 March Brussels Civil Society forum on drugs
11–12 March Copenhagen Steering Group meeting on Prison Health
11–18 March Vienna High-Level Segment and 52nd Session of the Commission on Narcotic Drugs
16 March The Hague Coordination meeting with Europol
19–20 March Helsinki Thematic meeting on ‘Hard drug use — what do we know?’
25–27 March Krakow European Conference of the Connections project
20 March Rome European Conference for the Presentation of the Report on the Status of Health in the 
European Union (MS)
23–24 March Vienna Global Smart Programme — Advisory Group Meeting, UNODC
25–26 March Brussels HIV/AIDS Think Tank meeting
29–31 March Madrid Conference on prison health
15–17 April Brussels Horizontal Drugs Group
23 April Brussels EMCDDA — DG JLS Coordination Meeting
23–24 April The Hague Cannabis expert meeting
27–28 April Vienna Technical seminar ‘Building the evidence base for drug control in Afghanistan’
29 April Neuchâtel Meeting of the GREA (Groupement Roman d’Etudes des Addictions)
29–30 April Prague National Drug Coordinators meeting/Symposium Meth/Amphetamines — Sharing the 
Experience
4–5 May Brussels HDG and Troika with Moldova/Belarus
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Date Venue Title
26–27 May Quito High Level Meeting of the Coordination and Cooperation Mechanism on Drugs, 
European Union — Latin America and the Caribbean
3–4 June Vienna Multi-city study for UNODC
5 June Porto Seminar of Public Health, Faculty of Medicine — Porto University
8–9 June Paris Expert meeting: ‘Réduction des risques chez le usagers de drogues’ and ‘Évaluation 
du Plan Gouvernemental 2008–2011’ (Plan Français)
9–10 June Paris 2nd Project Steering Committee meeting UNODC Cairo project
15–18 June Stockholm 3rd meeting of ECDC Advisory Group for Dublin Declaration on Partnership to fight 
AIDS
16 June Brussels Meeting of JHA Agency Directors
24–26 June Brussels HDG, Troika with US and European Action on Drugs
25–26 June The Hague Coordination meeting with Europol
30 June Brussels Working group on Alcohol, Drugs, Medicines and Driving
1 July The Hague 10th anniversary of Europol
6–8 July Vienna Expert Group Meeting on Drug Data Collection, UNODC
13 July Brussels Horizontal Drugs Group
15–16 September Brussels Horizontal Drugs Group
18 September Luxembourg 3rd Coordination Meeting EMCDDA–SANCO– ESTAT– JLS
18 September Paris Collège Scientifique — OFDT
24–25 September Brussels JLS conference ‘Bridging the Research Gap in the Field of Illicit Drugs in Europe’
28–29 September Bucharest ERA-TAIEX seminar series ‘The investigation and prosecution of drug trafficking in the 
EU’
29–30 September Lisbon CEPOL Euromed Police II, Maritime Drug Trafficking
5–9 October Linkoping ESF-LiU conference, the Changing Use and Misuse of Catha Edulis (Khat) in a 
Changing World
12–14 October Brussels WCO Permanent technical committee meeting
13 October Brussels ‘Réunion spéciale conjointe du Comité Technique Permanent/Comité de la Lutte Contre 
la Fraude’
14–15 October Brussels Technical Meeting on EU-LAC and Horizontal Drugs Group
14–15 October Luxembourg 3rd Health Information Committee Meeting and 1st Enlarged Health Information 
Committee Meeting (DG-SANCO)
20–23 October Barcelona International conference about surveys in the field of security
22–23 October Paris Expert Round Table on Western Europe
22–23 October The Hague Coordination meeting with Europol for the annual review of the list of new substances
22–23 October Valencia Monitoring system for alcohol, drugs and other psychoactive substance use: review of 
current practices
28 October Luxembourg Steering Committee on the European Health Survey System (EHSS)
28 October Madrid HIP network meeting
2–3 November Stockholm HIV in Europe 2009 Conference and drug coordinators meeting
2–3 November Strasbourg Pompidou Group Treatment Platform
11–12 November Brussels Horizontal Drug Group and EU/LAC Technical Committee
16–20 November Nicosia CEPOL seminar on Fighting against Drugs in the EU
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17–18 November Strasbourg 64th meeting of Pompidou Group permanent correspondents 
30 November–1 
December
Strasbourg Pompidou Group MedNET High Level Conference
7 December Edinburgh Scotland’s Drugs Conference 2009
8 December London UK Drugs RIWG Meeting
10–11 December Zagreb Taiex Seminar
16–17 December Luxembourg HIV/AIDS Think Tank meeting
18 December Paris ‘Epidemics, vaccination, addiction and mental health’, EHESP (Public Health Masters, 
Science-Po, Paris)
Key epidemiological indicators
29–30 January Vienna SDD Care meeting
12–13 February Montreux HIV/STI behavioural surveillance in Europe on behalf of the European Centre for 
Disease Prevention and Control (ECDC)
23–24 March Vienna HIV Situation and needs assessment in prison settings 
28–-30 April Vilnius 5th European Conference on Clinical and Social Research of AIDS and Drugs 
25–26 May Oslo Workshop: Enhancing estimation of incidence of problem drug use
1–5 June Copenhagen 35th Annual Alcohol Epidemiology Symposium of the Kettil Bruun Society (KBS 2009)
26 June Verona 4° congresso di Medicina delle Dipendenze
8–10 July Copenhagen UNAIDS/WHO Training Workshop on Methods for HIV Estimates and Projections
7–8 September Geneva Final meeting on Behavioural Surveillance related to HIV and STI in Europe
14–16 September Belfast ESSD 20th Annual Conference
7–9 October Las Palmas de Gran 
Canaria
XIII Congreso Nacional Sociedad Española de Toxicomanias — Foro Internacional
12–14 October Uppsala Strengthening Europe’s Defences against Communicable Diseases
12 November Cologne EATG Satellite: Treating HIV positive people injecting drugs in Europe: a mission 
possible 
26–27 November Berlin 3rd ECDC Advisory Group for the Monitoring of the Dublin Declaration on Partnership 
to Fight HIV/AIDS in Europe and Central Asia 
10–11 December Stockholm Scientific Symposium on HIV and STI in MSM and Annual Meeting on European HIV/
AIDS surveillance network 
Risk assessment and control of new psychoactive substances
24 April Utrecht Meeting at Utrecht on the Insight on new drugs
28–30 April Athens 15th ENFSI Drugs Working Group Meeting
20 May Vilnius European Information Day
18 September Ancona Psychonaut Web Mapping Project — 1st International Psychonaut Web Mapping 
Conference
Health and social responses 
21–23 January Berlin ‘Drug use: new forms, new answers, new politics’, Caritas Germany and Alice 
Salomon Hochschule Berlin
27 January Cologne Other countries, other addictions — do we need a European System of Addiction 
Care? (Andere Länder, andere Süchte — Oder: Brauchen wir eine europaïsche 
Suchtkrankenhilfe?)
5–6 February Bilbao 4th EU-Drug Addiction prevention trial SGC meeting
11 May Lisbon Improving harm reduction strategies in Europe: A Red Cross approach
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Date Venue Title
11–12 May Vicenza and 
Conegliano
Regional prevention conference on Selective prevention
11–13 May Nicosia Guidelines and Recommendations in Drug Treatment: Bridging the gap between 
clinical practice and evidence
12–13 May Berlin EU project and seminar on Social Inclusion
21–23 May Montenegro 4th Adriatic Drug Addiction Treatment Conference and 6th SEEA Symposium on 
Addictive Behaviours
4–5 June Brussels Briefing for experts: Drug Prevention and Information Programme
8–10 June Tutzing Scientific symposium of the German centre of addiction issues (Wissenschafliches 
Symposium de DHS)
1–4 July Porto CLAT 5 (Conferência Latina sobre Redução de Riscos)
9–10 July Brussels High-level Conference on Youth Health
3–4 September Santiago de 
Compostela
European Prevention Standards Project meeting
16–19 September Cologne 2nd German congress on Addiction (2. Deutscher Suchtkongress)
5–7 October Ljubljana 5th European Association of Addiction Therapy
11–15 October Rome Annual Conference of Italian Association of Psychiatry
12–27 October Paris ISPOR 12th Annual European Congress
14–15 October Vienna Extraordinary meeting of the Federal Drug Committee on Measures to reduce drug 
related deaths in Austria (Außerordentliche Sitzung des Bundesdrogenforums zum 
Themenschwerpunkt Maßnahmen zur Reduzierung der Drogentodesopfer in 
Österreich)
19–24 October Madrid XIII Congreso Nacional de Psiquiatria
29–31 October Madrid Conference on Prison Health Protection
1–4 November Lisbon Adapte Workshop at 6th International G-I-N conference
6–8 November Berlin 18th Congress of the German Society for Addiction Medicine (18. Kongress des 
Deutschen Gesellschaft für Suchtmedizin)
20–21 November Vienna Review of methods in addiction research (Methodenschau der Suchtforschung)
24 November Oslo Conference on Good prison health — better public health —safer society
2 December Münster Talking to experts (Kamingespräch) of the German Society for Social Work in 
Addiction Care (DG-SAS)
15–16 December Budapest Consumption rooms: perspectives in Europe and in Hungary
National drug strategies and legislation
12–14 February Innsbruck New way in drug policy (Neue Wege in Der Drogenpolitik)
26–28 March Salamanca Jornadas Nacionales de Socidrogalcohol
23–25 April Talinn 10th ENCP Regional meeting 
3 December Münster Conference ‘Crises as a chance’ (Krise als Chance)
Support to scientific research and publishing
26–27 January Paris 8th Research platform meeting, Pompidou Group
27 January Warsaw Interagency meeting
5–6 March Aarhus EMDAS meeting
25–26 March Paris 11th Expert meeting of the Pompidou Group committee on ethical issues and 
professional standards
5–10 May Halifax, Canada 31st Salis Conference
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27–28 May Strasbourg 63rd Permanent Correspondents meeting, Pompidou Group
31 May–4 June Copenhagen Kettil Bruun Society 2009 Symposium
16 July Dresden ESADD Opening Ceremony
24–27 September Trieste ISAJE Annual meeting
28–29 September Paris 9th meeting of the research platform, Pompidou Group
16 October Brussels ERA-Network meeting
21–22 October Paris 12th Expert meeting of the Pompidou Group committee on ethical issues and 
professional standards
22–23 October Brussels EUROLIB meeting
27 October Brussels DG RTD Socioeconomic Sciences and Humanities Information Day Addiction and 
lifestyles in contemporary European societies
11 November Brussels HDG meeting on drug research
26–27 November Lisbon EMDAS meeting
Reitox, enlargement and capacity building
17 February Tirana ESPAD crisis meeting
8–10 February Prague Coordination and preparatory meetings with Reitox Spokespersons and Workshop 
Joint Manual
25–26 February Brussels CARDS coordination meeting
3–4 March Munich IPA coordination meeting
30–31 March Belgrade UNODC Regional High-Level meeting
1–3 April Ankara Needs assessment meeting and Kick-off meeting of the Turkish Twinning Project
6–7 April Paris Workshops Joint Manual
8 May Brussels Bilateral meetings with Permanent Missions
16–19 May Washington Cooperation meeting CICAD, with focus on COPOLAD and Joint Manual
26–29 May Prague Workshop with Reitox Coaches before 40th Reitox HFP meeting and meeting with 
Czech focal point on Cannabis and Qualitative Research
14–17 June Athens 4th International Athens Conference on Project Management Best Practices and 
Workshop Joint Manual
21–23 June Brussels Workshop: Fight against drugs along the cocaine routes, opportunities and challenges 
for EC External Aid
26 June Ankara World Anti-Narcotics Day
7–8 September Bucharest Support to Romanian NFP
22–25 September Brussels Kick-off meeting Reitox Strategy with BMC
19 October Brussels Workshops on Joint Manual
19–20 October London Coordination and preparatory meetings with Reitox Spokespersons
22 October Sarajevo CARDS project final meeting
25–27 November Sintra Community agencies: Partners in accession (IPA II)
16–17 December Sarajevo Conference on regional strategy on justice and home affairs
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Annex 5 
Members of the EMCDDA’s statutory bodies
Members of the Management Board
The Management Board consists of one representative from each Member State, two 
representatives of the European Commission, two independent experts particularly 
knowledgeable in the field of drugs designated by the European Parliament and one 
representative from each country which has concluded an agreement with the EMCDDA. 
Non-voting observers, such as from international organisations with which the Centre 
cooperates, may be invited to the Management Board meetings.
Country Member Substitute
Belgium Claude GILLARD Philippe DEMOULIN
Bulgaria Tzveta RAICHEVA  
Czech Republic Kamil KALINA Lucia KISSOVA
Denmark Mogens JÖRGENSEN Mie SAABYE
Germany Sabine BÄTZING Dirk LESSER
Estonia Maris SALEKEŠIN Andri AHVEN
Ireland Eamon CORCORAN Alan BELL
Greece George FOTINOPOULOS Christos KOKORIS
Spain Carmen MOYA GARCIA Isabel NOGUER ZAMBRANO
France Didier JAYLE Julien EMMANUELLI
Italy Giovanni SERPELLONI Elisabetta SIMEONI
Cyprus Stelios SERGIDES
Latvia Maris TAUBE
Lithuania Audronė ASTRAUSKIENĖ Povilas RADZEVIČIUS
Luxembourg Marcel REIMEN Chairman Mike SCHWEBAG
Hungary Peter PORTÖRÖ
Malta Richard MUSCAT
Netherlands Marcel DE KORT
Austria Franz PIETSCH Johanna SCHOPPER
Poland Piotr JABŁOŃSKI Bogusława BUKOWSKA
Portugal João GOULÃO Manuel CARDOSO
Romania Doru DUMITRESCU Maximilian NICOLAE
Slovenia Vesna-Kerstin PETRIČ Jože HREN
Slovakia Zuzana MIKOVÁ Dana LÓZIOVÁ
Finland Tapani SARVANTI Kari HAAVISTO
Sweden Ralf LÖFSTEDT Vice-Chairman
United Kingdom Gabriel DENVIR John McCRACKEN
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Country Member Substitute
European Commission Aurel CIOBANU-DORDEA  
Carel EDWARDS 
Caroline HAGER 
Michael HÜBEL
European Parliament Carla ROSSI 
Wilmya ZIMMERMANN
Sylvie GEISMAR-WIEVIORKA 
Leopoldo GROSSO
Norwegian representatives Lilly Sofie OTTESEN Jon-Olav ASPÅS
Observers
Scientific Committee Michael FARRELL
Reitox Spokesperson Alan LODWICK
UNODC Gilberto GERRA
Council of Europe Pompidou Group Thomas KATTAU
WHO Haik NIKOGOSIAN
Turkey Celal BODUR
Members of the Executive Committee
The Executive Committee is made up of the Chairperson and the Vice-Chairperson of the 
Management Board, two other members of the Management Board representing the 
Member States and appointed by the Management Board and two representatives of the 
European Commission. The Executive Committee prepares the decisions of the Management 
Board, and assists and advises the Director.
Marcel REIMEN LU (Chairman of the Management Board)
Ralf LÖFSTEDT SE (Vice-Chairman of the Management Board)
Franz PIETSCH AT
Piotr JABŁOŃSKI PL
Aurel CIOBANU-DORDEA European Commission
Carel EDWARDS European Commission
Claude GILLARD BE (Chair of the Budget Committee, Observer)
João GOULÃO PT (Observer)
Wolfgang GÖTZ (Director)
Members of the EMCDDA Scientific Committee
The members of the Scientific Committee are selected for their independence and proven 
expertise in a particular field/speciality, as indicated below.
Issue Name Country
Legal and criminal justice Krysztof KRAJEWSKI Poland
Brice DE RUYVER Belgium
Risk assessment and basic 
research
Fernando RODRIGUEZ 
FONSECA
Spain
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Issue Name Country
Jean-Pol TASSIN France
Political and institutional 
framework
Henri BERGERON France
Irmgard EISENBACH-STANGL Austria
Henk GARRETSEN Netherlands
Epidemiology Marina DAVOLI Italy
Björn HIBELL Sweden
Dirk KORF Netherlands
Matthew HICKMAN UK
Methodological issues Gerhard BÜHRINGER Germany
John STRANG UK
Best practice and interventions Michael FARRELL Ireland
Richard VELLEMAN UK
Economic issues Anne-Line BRETTEVILLE JENSEN Norway
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Annex 6 
Use of the available resources in 2009
Activity-based management presentation of the EMCDDA 2009 budget in accordance with 
the content and costs of the 2009 work programme
ABM presentation of the EMCDDA 2009 budget in accordance with the content and costs of the 2009 work programme
Revenue
Initial budget 1st BRS 2nd BRS Final budget
EC subsidy (under budget lines 18 
07 01 01 and 18 07 01 02) 14 400 000 -63 000 14 337 000 Initial budget Budget 2009
Norwaycontribution 376 795 376 795 IPA 1 250 000 180 648
Turkey  contribution 100 000 -100 0 IPA 2 250 000 250 000
Total 14 876 795 -100 -63 000 14 713 795 CARDS 550 000 312 644
Expenditure (direct costs by programme commitments)
Programme
Title 1 —  Salaries allocated Title 1 —  
Salaries 
executed
Title 3 —  Activities allocated Title 3 —  
Activities 
executed
Total allocated
Total executed
Initial budget Final budget Initial budget Final budget Initial budget Final budget
EPI 1 964 135 1 752 175 1 736 791 264 180 260 634 258 269 2 228 315 2 234 483 1 995 060
RES 1 182 978 1 201 150 1 190 604 139 171 133 814 126 772 1 322 149 1 367 166 1 317 376
SCD 405 466 374 278 370 992 25 600 293 177 291 685 431 066 540 622 662 677
Reitox subvention 2 677 500 2 337 778 2 337 778
Programme
Title 1 —  Salaries allocated Title 1 —  
Salaries 
executed
Title 2 —  Functioning allocated Title 2 — 
Functioning 
executed
Title 3 — Activities allocated Title 3 — 
Activities 
executed
Total allocated
Total  executed
Initial budget Final budget Initial budget Final budget Initial budget Final budget Initial budget Final budget
Communication 853 210 835 881 828 542 0 42 934 40 683 943 001 1 199 009 1 193 353 1 796 211 2 094 501 2 062 578
Reitox 727 424 665 423 659 580 0 0 0 191 467 207 860 206 361 918 891 943 753 865 941
Programme
Title 1 — Salaries Title 1 — 
Salaries 
executed
Title 2 — Functioning allocated Title 2 — 
Functioning 
executed
Title 3 — Activities allocated Title 3 — 
Activities 
executed
Total  allocated
Total executed
Initial budget Final budget Initial budget Final budget Initial budget Final budget Initial budget Final budget
Direction 778 858 786 294 779 390 0 0 0 334 592 201 369 199 936 1 113 450 984 079 979 326
Administration 1 790 884 2 091 990 2 073 622
1 284 119 870 094 815 370 63 897 131 602 123 856 3 203 900 3 021 231 3 116 819
Administration (training and recruitment) 65 000 104 291 103 971
ICT 629 495 666 467 660 615 521 459 537 050 453 830 34 358 20 524 19 375 1 185 312 1 190 182 1 133 820
Programme Title 1 — Salaries Title 2 — Functioning
Title 2 — 
Functioning 
executed
Title 3 — Activities
Title 3 — 
Activities 
executed
Total 
programme 
direct costs
Total programme  
direct costs executed 
IPA 1 8 080 7 200 500 172 068 180 648 178 306
IPA 2 36 900 36 630 1 000 0 212 100 210 141 250 000 246 771
CARDS 7 200 7 200 2 000 1 000 303 444 281 644 312 644 289 844
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Activity-based management presentation of the EMCDDA 2009 budget in accordance with 
the content and costs of the 2009 work programme
ABM presentation of the EMCDDA 2009 budget in accordance with the content and costs of the 2009 work programme
Revenue
Initial budget 1st BRS 2nd BRS Final budget
EC subsidy (under budget lines 18 
07 01 01 and 18 07 01 02) 14 400 000 -63 000 14 337 000 Initial budget Budget 2009
Norwaycontribution 376 795 376 795 IPA 1 250 000 180 648
Turkey  contribution 100 000 -100 0 IPA 2 250 000 250 000
Total 14 876 795 -100 -63 000 14 713 795 CARDS 550 000 312 644
Expenditure (direct costs by programme commitments)
Programme
Title 1 —  Salaries allocated Title 1 —  
Salaries 
executed
Title 3 —  Activities allocated Title 3 —  
Activities 
executed
Total allocated
Total executed
Initial budget Final budget Initial budget Final budget Initial budget Final budget
EPI 1 964 135 1 752 175 1 736 791 264 180 260 634 258 269 2 228 315 2 234 483 1 995 060
RES 1 182 978 1 201 150 1 190 604 139 171 133 814 126 772 1 322 149 1 367 166 1 317 376
SCD 405 466 374 278 370 992 25 600 293 177 291 685 431 066 540 622 662 677
Reitox subvention 2 677 500 2 337 778 2 337 778
Programme
Title 1 —  Salaries allocated Title 1 —  
Salaries 
executed
Title 2 —  Functioning allocated Title 2 — 
Functioning 
executed
Title 3 — Activities allocated Title 3 — 
Activities 
executed
Total allocated
Total  executed
Initial budget Final budget Initial budget Final budget Initial budget Final budget Initial budget Final budget
Communication 853 210 835 881 828 542 0 42 934 40 683 943 001 1 199 009 1 193 353 1 796 211 2 094 501 2 062 578
Reitox 727 424 665 423 659 580 0 0 0 191 467 207 860 206 361 918 891 943 753 865 941
Programme
Title 1 — Salaries Title 1 — 
Salaries 
executed
Title 2 — Functioning allocated Title 2 — 
Functioning 
executed
Title 3 — Activities allocated Title 3 — 
Activities 
executed
Total  allocated
Total executed
Initial budget Final budget Initial budget Final budget Initial budget Final budget Initial budget Final budget
Direction 778 858 786 294 779 390 0 0 0 334 592 201 369 199 936 1 113 450 984 079 979 326
Administration 1 790 884 2 091 990 2 073 622
1 284 119 870 094 815 370 63 897 131 602 123 856 3 203 900 3 021 231 3 116 819
Administration (training and recruitment) 65 000 104 291 103 971
ICT 629 495 666 467 660 615 521 459 537 050 453 830 34 358 20 524 19 375 1 185 312 1 190 182 1 133 820
Programme Title 1 — Salaries Title 2 — Functioning
Title 2 — 
Functioning 
executed
Title 3 — Activities
Title 3 — 
Activities 
executed
Total 
programme 
direct costs
Total programme  
direct costs executed 
IPA 1 8 080 7 200 500 172 068 180 648 178 306
IPA 2 36 900 36 630 1 000 0 212 100 210 141 250 000 246 771
CARDS 7 200 7 200 2 000 1 000 303 444 281 644 312 644 289 844
Final budget
General	report	of	activities	2009
74
Budget out-turn account for the financial year 2009: revenue and expenditure (provisional)
2009 2008
Revenue
Commission subsidy (for the operating budget — Titles 1, 2 and 3 of the agency) + 14 150 000.00 13 919 600.00
Phare funds from the Commission + 149 400.00
Other contributions and funding received via the Commission + 450 810.00 494 190.00
Other donors + 376 795.00 461 414.00
Fee income +
Other revenue + 205 798.31
Total revenue (a) 15 183 403.31 15 024 604.00
Expenditure
Title I: Staff
Payments - 8 413 498.37 7 826 805.95
Appropriations carried over - 59 408.05 57 648.49
Title II: Administrative expenses
Payments - 976 986.47 1 086 963.62
Appropriations carried over - 345 408 94 901 006.93
Title III: Operating expenditure 
Payments - 5 261 522.49 4 869 955.76
Appropriations carried over - 371 141 68 601 515.28
Total expenditure (b) 15 427 966.00 15 343 896.03
Out-turn for the financial year (a-b) -244 562.69 -319 292.03
Cancellation of unused payment appropriations carried over from previous year + 136 601.01 87 685.39
Adjustment for carry-over from the previous year of appropriations available at 31.12 
arising from assigned revenue + 626 438.16 400 484.50
Exchange differences for the year (gain +/loss -) +/- 779.15 2 798.93
Adjustments: PHARE 4 cancel-Norway grant 2009+ assigned revenue (internal + external) -292 089.50 59 170.59
Balance of the out-turn account for the financial year 227 166.13 230 847.38
Balance year N-1 +/-
Positive balance from year N-1 reimbursed in year N to the Commission -
Result used for determining amounts in general accounting 227 166.13 230 847.38
Commission subsidy — agency registers accrued revenue and Commission accrued expense 13 922 833.87
Pre-financing remaining open to be reimbursed by the agency to the Commission in year N+1 227 166.13
Not included in the budget out-turn: 
Interest generated by 31/12/09 on the Commission subsidy funds and to be reimbursed to 
the Commission (liability)
+ 30 643.36 108 053.68
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2009 budget appropriations and execution by nature of expenditure
Financial and accounting management
A budget of EUR 14 713 795 was adopted for the implementation of the 2009 work 
programme. The budgetary figures for 2009 are presented in the tables below.
Budgetary provisions and appropriations, 2009
Title Description EUR
 1. Expenditure relating to persons working with the office
• Staff in active employment
• Other staff-related expenditure (exchange of officials, etc.)
8 456 747
21 203
Total under Title 1 8 477 950
 2. Buildings, equipment and sundry operating expenditure 
• Investment in immovable property, rental of buildings and associated costs
• Data processing
• Movable property and associated costs
•  Current administrative expenditure + postal charges and 
telecommunications
• Socio-medical infrastructure
590 504
513 459
111 600
179 912
54 603
Total under Title 2 1 450 078
 3. Expenditure resulting from special functions carried out by the institution
• Statutory meetings
• Expenditure on formal and others meetings + representative expenses
• Studies, surveys, consultations 
• Publishing
• European Network on Drugs and Drug Addiction (Reitox)
• Missions
270 000
479 368
208 896
1 142 102
2 337 777
347 624
Total under Title 3 4 785 767
Total core budget 14 713 795
 4. Expenditure relating to other subsidies
• EC financing of specific projects
• IPA (Instrument for Pre-Accession) programme
0
10. Other expenses (reserve)
Total budget 14 713 795
Execution of budget: credit consumption (commitments), 2009
Title Description % consumption  of available credits
1. Staff Staff salaries, allowances, etc. 99.20
2. Buildings, equipment and sundry operating expenditure 80.04
3. Operating expenditure 99.00
4. Expenditure relating to other subsidies
Total consumption (Titles 1, 2, 3 ) 98.39
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EMCDDA balance sheet at 31 December 2009 (provisional)
Assets
31.12.2009 31.12.2008 Variation
A. Non-current assets
Intangible fixed assets 301 868.74 466 440.54 -164 571.80
Tangible fixed assets 2 625 036.07 2 687 672.01 -62 635.94
Land and buildings 2 267 516.80 2 359 006.33 -91 489.53
Plant and equipment 32 766.36 14 630.62 18 135.74
Computer hardware 198 221.29 295 235.38 -97 014.09
Furniture and vehicles 126 531.62 18 799.68 107 731.94
Other fixtures and fittings 0.00 0.00 0.00
Leasing 0.00 0.00 0.00
Tangible fixed assets under construction 0.00 0.00 0.00
Investments 0.00 0.00 0.00
Guarantee Fund 0.00
Investments in associates 0.00
Interest in joint ventures 0.00
Other investments 0.00 0.00 0.00
Loans 0.00 0.00 0.00
Loans granted from the budget 0.00 0.00 0.00
Loans granted from borrowed funds 0.00 0.00 0.00
Long-term pre-financing 0.00 0.00 0.00
Long-term pre-financing 0.00 0.00 0.00
Long-term pre-financing with consolidated EU entities 0.00 0.00 0.00
Long-term receivables 0.00 0.00 0.00
Long-term receivables 0.00 0.00 0.00
Long-term receivables with consolidated EU entities 0.00 0.00 0.00
Total non-current assets 2 926 904.81 3 154 112.55 -227 207.74
B. Current assets
Stocks 0.00 0.00 0.00
Short-term pre-financing 0.00 0.00 0.00
Short-term pre-financing 0.00 0.00 0.00
Short-term pre-financing with consolidated EU entities 0.00 0.00 0.00
Short-term receivables 655 360.74 955 612.98 -300 252.24
Current receivables 558 238.93 849 563.70 -291 324.77
Long-term receivables falling due within a year 0.00
Sundry receivables 0.00 0.00 0.00
Other 97 121.81 106 049.28 -8 927.47
Accrued income 0.00
Deferred charges 27 661.76 35 773.33 -8 111.57
Deferrals and Accruals with consolidated EU entities 69 460.05 70 275.95 -815.90
Short-term receivables with consolidated EU entities 0.00 0.00 0.00
Short-term investments 0.00 0.00 0.00
Cash and cash equivalents 1 255 148.58 1 635 537.86 -380 389.28
Total current assets 1 910 509.32 2 591 150.84 -680 641.52
Total assets 4 837 414.13 5 745 263.39 -907 849.26
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Liabilities
31.12.2009 31.12.2008 Variation
A. Capital 2 923 169.36 3 259 134.41 -335 965.05
Reserves 0.00 0.00 0.00
Accumulated surplus/deficit 3 259 134.41 2 782 804.39 476 330.02
Economic result of the year —  profit+/loss -335 965.05 476 330.02 -812 295.07
0.00
B. Minority interest 0.00
0.00
C. Non-current liabilities 70 000.00 0.00 70 000.00
Employee benefits 0.00 0.00 0.00
Provisions for risks and charges 70 000.00 0.00 70 000.00
Financial liabilities 0.00 0.00 0.00
Borrowings 0.00 0.00 0.00
Held-for-trading liabilities 0.00 0.00 0.00
Other long-term liabilities 0.00 0.00 0.00
Other long-term liabilities 0.00 0.00 0.00
Other long-term liabilities with consolidated EU entities 0.00 0.00 0.00
Pre-financing received from consolidated EU entities 0.00 0.00 0.00
Other long-term liabilities from consolidated EU entities 0.00 0.00 0.00
Total A+B+C 2 993 169.36 3 259 134.41 -265 965.05
0.00
D. Current liabilities 1 844 244.77 2 486 128.98 -641 884.21
Provisions for risks and charges 0.00 0.00 0.00
Financial liabilities 0.00 0.00 0.00
Borrowings falling due within the year 0.00 0.00 0.00
Held-for-trading liabilities due within the year 0.00 0.00 0.00
Other current financial liabilities 0.00
Accounts payable 1 844 244.77 2 486 128.98 -641 884.21
Current payables 31 874.46 453 690.44 -421 815.98
Long-term liabilities falling due within the year 0.00 0.00 0.00
Sundry payables 0.00 0.00 0.00
Other 1 550 390.18 1 545 705.05 4 685.13
Accrued charges 1 533 953.29 1 545 241.05 -11 287.76
Deferred income 16 436.89 464.00 15 972.89
Deferrals and accruals with consolidated EU entities 0.00 0.00
Accounts payable with consolidated EU entities 261 980.13 486 733.49 -224 753.36
Pre-financing received from consolidated EU entities 227 166.13 379 142.18 -151 976.05
Other accounts payable against consolidated EU entities 34 814.00 107 591.31 -72 777.31
Total current liabilities 1 844 244.77 2 486 128.98 -641 884.21
0.00
Total 4 837 414.13 5 745 263.39 -907 849.26
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List of 2009 negotiated procedures
Supplies Services Total
Number of 
contracts
Volume of 
contracts 
(EUR)
Number of 
contracts
Volume of 
contracts 
(EUR)
Number of 
contracts %
Volume of 
contracts 
(EUR)
>5 000 & <25 000 EUR 2 36 066.05 25 207 814.43 27  87 243 880.48
=/>25 000 EUR 0 0.00  4 219 305.34  4  13 219 305.34
Total 2 36 066.05 29 427 119.77 31 100 463 185.82
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Annex 7 
List of acronyms and abbreviations
ABAC-SAP EC budget and accrual-based accountancy system
AIDCO EuropeAid co-operation office (European Commission)
AIDS Acquired Immune Deficiency Syndrome
AR EMCDDA Annual report
BZP Benzylpiperazine
CARDS  Community Assistance for Reconstruction, Development and Stabilisation 
(in the Balkans)
CEPOL European Police College
CICAD Inter-American Drug Abuse Control Commission
CLAT Conferência Latina sobre Redução de Riscos
CMA content management application
CND  UN Commission on Narcotic Drugs
COM EMCDDA Communication unit
DG JLS Directorate-General for Justice, Freedom and Security
DG Research Directorate-General for Research
DG SANCO Directorate-General of Health and Consumer Protection
DRD drug-related deaths
DRID drug-related infectious diseases
DRUID driving under the influence of drugs, alcohol and medicines
EC European Commission
ECDC European Centre for Disease Prevention and Control
EDND European Database on New Drugs
EIB Evaluation instruments bank
ELDD European Legal Database on Drugs
EMCDDA European Monitoring Centre for Drugs and Drug Addiction
EMDAS European Masters on Drugs and Alcohol Studies
EMA European Medicines Agency
ENFSI European Network of Forensic Science Institutes
EP European Parliament
EPI Epidemiology, crime and markets unit
ESADD European Post-Graduate School in Addiction Research
ESPAD European School Survey Project on Alcohol and Drugs
EU European Union
EUROLIB a grouping of European institutional libraries
Eurostat the statistical arm of the European Community
EWS early warning system
GPS general population surveys
HBSC Health Behaviour in School-aged Children
HCIN Heads of Communication and Information Network
HCV Hepatitis C virus
HDG Horizontal Drugs Group
HFP Head of national focal point
HIV Human Immunodeficiency Virus
IAS Internal Audit Service
ICT information and communication technology
IDT (Portuguese) Instituto de Drogas e Toxicodependências
IDU injecting drug use 
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IPA Instrument for Pre-accession Assistance
ISAJE International Society of Addiction Journal Editors
ISSDP International Society for the Study of Drug Policy
JHA Justice and Home Affairs
LAC Latin America and the Caribbean
MB Management Board
MoU Memorandum of Understanding
MS Member State
NDO National drug observatories
NFP national focal point
OFDT French national focal point
OJ Official Journal of the European Union
PDU problem drug use
PERK Prevention and evaluation resources kit
Reitox European information network on drugs and drug addiction
RES Interventions, law and policies unit
RTX the Reitox unit of the EMCDDA
SALIS Substance Abuse Librarians and Information Specialists
SCD Scientific partners and documentation unit
SI Selected issues
SQ Structured questionnaire
ST Standard Tables
STI sexually transmitted infections
TB Tuberculosis
TDI treatment demand indicator
UN United Nations
UNAIDS Joint United Nations Programme on HIV/AIDS
UNGASS United Nations General Assembly Special Session
UNODC United Nations Office on Drugs and Crime
WCO World Customs Organization
WHO World Health Organization
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